Glycolytic flux controls retinal progenitor cell differentiation via regulating Wnt signaling

Joseph Hanna[1,2,3], Yacine Touahri[1,3,4], Alissa Pak[1,2], Lauren Belfiore[1,2], Edwin van Oosten[1,4], Luke Ajay David[1,2,3], Sisu Han[5], Yaroslav Ilnytskyy[6], Igor Kovalchuk[6], Deborah M Kurrasch[5], Satoshi Okawa[7,8,9,10], Antonio del Sol[10,11,12], Robert A Screaton[1,4], Isabelle Aubert[1,2], Carol Schuurmans[1,2,3,4]*

[1]Biological Sciences, Sunnybrook Research Institute, 2075 Bayview Ave, Toronto, ON, M4N 3M5, Canada
[2]Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, M5S 1A8, Canada
[3]Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, M5T 3A9, Canada
[4]Department of Biochemistry, University of Toronto, Toronto, ON, M5S 1A8, Canada
[5]Department of Medical Genetics, Hotchkiss Brain Institute, Alberta Childrens' Hospital Research Institute, University of Calgary, Calgary, AB, T2N 1N4, Canada
[6]Department of Biological Sciences, University of Lethbridge, Lethbridge, AB, T1K 3M4, Canada
[7]Pittsburgh Heart, Lung, and Blood Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
[8]Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
[9]McGowan Institute for Regenerative Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
[10]Computational Biology Group, Luxembourg Centre for Systems Biomedicine, U of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg
[11]CIC bioGUNE, Bizkaia Technology Park, 48160 Derio, Spain
[12]IKERBASQUE, Basque Foundation for Science, Bilbao 48013, Spain

*To whom correspondence should be addressed: Carol Schuurmans, Sunnybrook Research Institute, 2075 Bayview Ave, Room A340**,** Toronto, ON, M4N 3M5**.** Phone: (416) 480-6100
E-mail: cschuurmans@sri.utoronto.ca

Author Contributions: Conceptualization: JH, CS; Methodology: JH, YT, AP, LB, EvO, LAD, SH, YI, IK, DMK, SO, AdS, RS, CS; Investigation: JH, YT, AP, EvO, LAD, SH, YI, SO; Visualization: JH, YT, AP, LB, SH, LAD; Funding acquisition: IA, RS, CS; Project administration: CS; Supervision: CS, RS, IA, IK, DK, AdS; Writing – original draft: JH, CS; Writing – review & editing: JH, YT, AP, LB, EvO, LAD, SH, YI, IK, DMK, SO, AdS, IA, RS, CS. All the authors contributed to intellectual discussions and the direction of the project.

Competing Interest Statement: All authors declare they have no actual or potential competing interests.

Keywords: *Pten*, retinal progenitor cells, glycolysis, intracellular pH, photoreceptor differentiation, rod outer segments, Wnt signaling

This PDF file includes:
Main text
Figures 1 to 7
Word count: 5160 (excluding materials and methods)

ABSTRACT

Metabolic pathways are remodeled in response to energy and other homeostatic demands and are
dynamically regulated during embryonic development, suggesting a role in guiding cellular
differentiation. Here, we show that glycolytic flux is required and sufficient to bias multipotent
retinal progenitor cells (RPCs) to acquire a rod photoreceptor fate in the murine retina. In an
RPC-specific conditional knock-out of *Phosphatase and tensin homolog* (*Pten*-cKO) and an
RPC-specific conditional gain-of-function of dominant active *PFKB3* (cyto*PFKB3*), glycolytic
gene expression and activity are elevated, correlating with precocious rod photoreceptor
differentiation and outer segment maturation. Conversely, glycolytic inhibition in retinal
explants, achieved either with 2-deoxy-d-glucose, a competitive inhibitor of glucose metabolism,
by lowering media pH, which disables PKM2, a rate-limiting enzyme, or by inhibiting lactate/H^+
symporters, which lowers intracellular pH, suppresses RPC proliferation and photoreceptor
differentiation. Mechanistically, we show that Wnt signaling, the top-upregulated pathway in
Pten-cKO retinas, is a glycolysis-dependent pathway. Pharmacological and genetic perturbation
of Wnt signaling using a *Ctnnb1*-cKO phenocopies glycolytic inhibition, suppressing RPC
proliferation, photoreceptor differentiation and outer segment maturation. Thus, developmental
rewiring of glycolytic flux modulates Wnt signaling to drive rod photoreceptor differentiation
and maturation, an instructive role that may be exploited therapeutically for cell replacement
strategies.

IMPACT STATEMENT

Transgenic and pharmacological approaches reveal developmental elevations in glycolytic flux
have an instructive role in promoting rod photoreceptor differentiation and maturation via
activation of Wnt signaling.

INTRODUCTION

Multiple neural cell types comprise the mature retina, all of which must be produced in correct numbers with precise identities for effective visual processing. Included are rod and cone photoreceptors, the light-sensing neurons; amacrine, bipolar and horizontal cells, retinal interneurons; ganglion cells, the output neurons of the retina; and supportive glial cells known as Müller glia. Clonal analyses across vertebrate species have revealed that all seven retinal cell types are derived from multipotent retinal progenitor cells (RPCs) that give rise to clones of varying sizes and compositions (Alexiades & Cepko, 1997; Fekete et al., 1994; Gomes et al., 2011; Holt et al., 1988; Jensen & Raff, 1997; Turner & Cepko, 1987; Turner et al., 1990; Wetts & Fraser, 1988). In mice, RPCs begin to differentiate at embryonic day (E) 12, completing their proliferation and differentiation by postnatal day (P) 10 -12 (Cepko, 2014; Young, 1985; X. Zhang et al., 2023). Symmetric proliferative (P/P) divisions predominate early in development, followed by a shift to asymmetric (P/D) divisions that renew the RPC pool and generate differentiated cells, and finally, by symmetric differentiative (D/D) divisions that generate two postmitotic cells (Baye & Link, 2007; Nerli et al., 2020; Paolini et al., 2015). At each stage, individual RPC fate decisions are largely stochastic, albeit with temporal biases, such that the seven retinal cell types are born in overlapping windows (Gomes et al., 2011; He et al., 2012). Ganglion, horizontal and cone cells are born in the earliest embryonic stages, followed closely by amacrine cells, and finally by bipolar cells, rods and Müller glia, which mainly differentiate in the first two postnatal weeks (Rapaport et al., 2004; Young, 1985). How RPCs interpret extrinsic signals and intrinsic contextual cues to ultimately produce the correct numbers of each retinal cell type remains incompletely understood.

Cellular energy and precursor metabolites are produced by the metabolism of glucose, which is converted into pyruvate via glycolysis. Glycolysis is a multi-step enzymatic process that occurs in the cytosol, does not require O_2, and produces 2 molecules of ATP per glucose molecule (Hanna et al., 2022). Pyruvate is either transported to mitochondria for further oxidation to drive oxidative phosphorylation (OXPHOS) by the electron transport chain, or converted to lactate and secreted out of the cell. OXPHOS is an O_2-dependent metabolic pathway that produces 30-38 ATP molecules for each glucose molecule, and hence, produces more cellular energy than glycolysis (Hanna et al., 2022). Yet, the majority of vertebrate retinal cells rely on glycolysis as the main metabolic pathway, even in the presence of O_2 (Hurley et al., 2015). The preference for aerobic glycolysis has been termed the Warburg effect, an adaptation commonly observed in cancer cells that is also used by some 'normal' cells (Vander Heiden et al., 2009; Warburg, 1956a, 1956b). Included are dividing neural progenitor cells, which use aerobic glycolysis for energy production across tissue types, including in the retina (Hanna et al., 2022). In Xenopus, RPCs rely on glycogen stores as a fuel source for glycolysis (Agathocleous et al., 2012), whereas in human retinal organoids, glucose is the essential fuel, and is required for RPC expansion at the earliest stages of optic vesicle formation (Takata et al., 2023). Finally, during murine retinal development, mitophagy clears mitochondria to drive a metabolic shift towards glycolysis, which supports early RPC differentiation into ganglion cells (Esteban-Martinez et al., 2017). However, whether metabolic reprogramming and levels of glycolytic activity influence RPC differentiation decisions during later developmental stages is not known.

Metabolic reprogramming, or alterations in metabolic rates and/or pathways, occurs in stem and progenitor cells during tissue development (Tatapudy et al., 2017), including in the retina (Esteban-Martinez et al., 2017). In a few lineages, metabolism has been ascribed

instructive roles in driving cellular differentiation, including in skeletal muscle and helper T cell
lineages (Peng et al., 2016; Ryall et al., 2015; Tatapudy et al., 2017). In these lineages, glycolysis
is important for more than energy production, for instance, modifying histone acetylation in
murine skeletal muscle (Ryall et al., 2015), activating Wnt signaling to control chick
neuromesodermal progenitor cell fate choice (Oginuma et al., 2020), and altering protein
subcellular localization in the murine presomitic mesoderm (Miyazawa et al., 2022). To further
investigate how developmental signaling pathways intersect with metabolism to control RPC fate
choice in the retina, we focused on PTEN, an intracellular protein and lipid phosphatase with
pleiotropic actions, including the direct inhibition of glycolysis through dephosphorylation and
consequent inactivation of phosphoglycerate kinase 1 (PGK1), a rate-limiting glycolytic enzyme
(Qian et al., 2019). In *Pten* conditional knockout (KO) retinas, RPCs proliferate excessively
early in embryonic development, accompanied by the accelerated differentiation of
photoreceptors in the outer nuclear layer (ONL) (Cantrup et al., 2012; Jo et al., 2012; Tachibana
et al., 2016; Tachibana et al., 2018). Here, we show that elevated glycolysis accompanies the
accelerated RPC differentiation kinetics in *Pten*-cKO retinas, which ultimately results in the
precocious depletion of the RPC pool. Similarly, in an RPC-specific, conditional gain-of-
function model of dominant active *PFKB3* (cyto*PFKB3*), glycolytic gene expression and activity
are elevated, correlating with precocious rod photoreceptor differentiation and outer segment
(OS) maturation. Conversely, multiple inhibitors of glycolysis reduce RPC proliferation and
photoreceptor differentiation. Finally, we found that glycolysis is required and sufficient to
control Wnt signaling, and show that Wnt activity is required for rod photoreceptor
differentiation and OS maturation. We have thus uncovered a novel glycolytic flux-Wnt axis as
an important regulator of RPC fate choice.

RESULTS

Elevated glycolysis and accelerated rod photoreceptor differentiation correlate in *Pten*-
cKO retinas

Neural progenitor cells in the embryonic brain (Khacho & Slack, 2018) and retina
(Agathocleous et al., 2012) preferentially use glycolysis for energy production. However,
glycolytic metabolites and glycolytic gene expression are not at uniform levels throughout retinal
development, peaking at E18.5-P0 (Esteban-Martinez et al., 2017). Since these measurements
were performed in bulk, and the ratio of RPCs to differentiated cells declines as development
proceeds, it is not clear whether glycolytic activity is temporally regulated within RPCs or in
other retinal cell types. To assess glycolytic gene expression in RPCs at different stages of
development, we mined scRNA-seq data collected from wild-type retinas between E11 and P14
(Clark et al., 2019). High dimensional uniform manifold approximation and projection (UMAP)
plots identified unique cell clusters corresponding to pre-neurogenic (pre-N) RPCs at E11, early-
RPCs from E12-E18 and late-RPCs from P0-P5, all of which expressed *Cdk1*, a marker of active
cell proliferation (Figure 1A,B). Feature plots were used to examine glycolytic gene expression
in retinal cell types (Figure 1B). Several glycolytic genes were specifically enriched in early
compared to late RPC clusters, most notably including *Pgk1,* a rate-limiting enzyme that
catalyzes the first ATP-producing step in the glycolytic chain reaction, and *Eno1*, a rate-limiting
enzymes in glycolysis (Figure 1B). A less obvious bias towards early RPC expression was
observed for *Hk1*, the initial enzyme in the glycolytic pathway that converts glucose to glucose-
6-phosphate, *Pfk1*, another rate-limiting enzyme in glycolysis, and *Slc16a3,* encoding the

lactate/H$^+$ symporter that shuttles lactate together with a H$^+$ ion (Figure 1B). In contrast, *Aldoa*
and *Ldhb* showed similar expression levels between pre-N, early and late RPCs (Figure 1B).
These data suggest that glycolytic activity peaks during the early-to-late RPC transition.

We noted that the highest levels of *Pgk1* expression at E18/P0 corresponded to the known
pinnacle of RPC differentiation into committed, rod photoreceptor precursors (Kim et al., 2016)
(Figure 1C), which undergo a protracted differentiation period, only expressing mature
photoreceptor markers between P2 and P8 (e.g., *Prph2, Impg2, Pde6g, Gm11744, Gnat2*; Figure
1-figure supplement 1). We thus asked whether levels of glycolytic activity have an instructive
role in rod photoreceptor fate selection. To test this hypothesis, we used two genetic models to
elevate glycolytic activity in RPCs. We first targeted PTEN, a phosphatase that dephosphorylates
and inactivates PGK1, a rate-limiting step (K. Zhang et al., 2023). PTEN is expressed throughout
retinal development (Figure 1-figure supplement 1), including in late-RPCs (E18.5), which co-
express VSX2 and PAX6 (Figure 1D). To delete *Pten* in RPCs, we generated a *Pten*-cKO model
by crossing a floxed allele of *Pten,* in which exons 4 and 5 were flanked by loxP sites, with a
Pax6-Cre-GFP driver allele (Figure 1E). As a proxy of Cre activity, GFP was expressed in RPCs
and postmitotic newborn cells with a high peripheral to central gradient in *Pax6-Cre-GFP*
transgenics (Figure 1F). Thus, for the remainder of this study, we focused on the peripheral
retina where the *Pax6-Cre* allele was most active, avoiding the central retina, which was readily
distinguishable as it forms a visible hamartoma comprised of remaining wild-type cells in *Pten*-
cKO retinas (Tachibana et al., 2018).

Using cellular birthdating, we previously showed that *Pten*-cKO RPCs are
hyperproliferative and differentiate on an accelerated schedule between E12.5 and E18.5, yet
fewer rod photoreceptors are ultimately present in P7 retinas (Tachibana et al., 2016). Since
retinal cell differentiation persists into the early postnatal period, we conducted similar
birthdating experiments, but instead administered BrdU to P4 pups. In wild-type retinas
harvested at P14, BrdU cells were mainly distributed between the INL, where late-born bipolar
cells and Müller glia localize, and the ONL, where rod photoreceptors migrate (Figure 1G,H).
Labeled cells in the GCL likely represent displaced amacrine cells, which are at the end of their
differentiation window. In contrast, only a few BrdU-labeled cells were detected in the GCL in
Pten-cKO retinas, with no BrdU$^+$ cells present in the INL and ONL (Figure 1G,H). Thus, the
accelerated differentiation observed during embryonic stages is followed by the precocious
depletion of dividing RPCs in *Pten*-cKO retinas by the early postnatal period, effectively limiting
the overall period of rod photoreceptor differentiation (Figure 1I).

Glycolytic gene expression and activity are upregulated in P0 *Pten*-cKO retinas

To investigate how *Pten,* encoding an intracellular phosphatase, controls the timing of
RPC proliferation and differentiation, we began with a transcriptomic approach. To decipher
transcriptomic changes associated with *Pten* loss, we performed bulk RNA sequencing (RNA-
seq) on P0 wild-type (N=4) and *Pten*-cKO (N=5) retinas. A heatmap depiction revealed that
there are distinct blocks of expressed genes in the two genotypes (Figure 2A, Figure 2– Data
supplement 1). Among the differentially expressed genes (DEGs) with a log2-fold change
(log2FC) ≥2 between wild-type and *Pten*-cKO retinas, there were 408 down-regulated and 667
up-regulated genes (Figure 2B). To draw relationships between genes and pathways, we analysed
the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, showing enrichment of terms

such as *axon guidance*, and *regulation of actin cytoskeleton* among the DEGs. In addition,
metabolic pathway terms were enriched, including *glycolysis* (Figure 2C), which involves a
series of enzymatic reactions that break down glucose into pyruvate for energy production
(Figure 2D). Indeed, analysis of Reads Per Kilobase per Million mapped reads (RPKM) revealed
that most of the glycolytic regulatory enzymes were upregulated in *Pten*-cKO retinas, including
Hk1, Gpi1, Pfkl, Aldoa, Pgk1, Pgam1, and *Eno1,* although others, such as *Pkm,* were not
differentially expressed (Figure 2E). Additionally, expression of *Slc16a3*, encoding a
monocarboxylate transporter that symports lactate and one hydrogen ion outside of the cell, was
increased in *Pten*-cKO retinas (Figure 2E). We validated these increases in gene expression for a
handful of genes, including *Hk1, Pgk1, Eno1,* and *Slc16a3,* using qPCR, confirming that these
glycolytic genes were indeed upregulated in E15.5 *Pten*-cKO retinas (Figure 2F).

To test whether transcriptomic changes in P0 *Pten*-cKO retinas reflected an increase in
glycolytic activity, we performed a Seahorse assay. Extracellular acidification rate (ECAR) was
elevated in P0 *Pten*-cKO RPCs compared to controls, indicative of an increase in lactic acid
levels, which serves as a proxy measure for glycolysis (Figure 2G). We further assessed
mitochondrial O_2-consumption rates in P0 retinal cells, showing that oligomycin, an ATP
synthase inhibitor, suppressed basal respiration rates to the same extent in wild-type and *Pten*-
cKO retinas (Figure 2G). Similarly, maximum or spare respiratory capacity measured upon
stimulation did not differ between P0 wild-type and *Pten*-cKO retinas (Figure 2G). Finally, we
used a colorimetric assay to measure lactate levels in tissue lysates, revealing an elevation of
lactate in *Pten*-cKO retinas compared to wild-type retinas at P0 (Figure 2H). Taken together,
these data indicate that glycolytic gene expression and activity are elevated in *Pten*-cKO retinas,
whereas oxygen-dependent OXPHOS is unaffected.

Pharmacological inhibition of glycolysis decreases RPC proliferation and photoreceptor differentiation

To assess the requirement for glycolysis in P0 RPCs, we used a retinal explant assay
(Figure 3A), growing explants from P0 retinas for 24 hrs in the presence of 5 mM and 10 mM 2-
deoxy-d-glucose (2DG), a competitive inhibitor of the conversion of glucose to glucose-6-
phosphate, the first step in glycolysis (Figure 3B). To label dividing RPCs, explants were
exposed to BrdU, which is incorporated into S-phase cells, for 30 minutes prior to harvesting.
2DG treatment resulted in a dose-dependent inhibition of RPC proliferation as evidenced by a
reduction in BrdU$^+$ cells (Figure 3C). To determine whether glycolytic inhibition reduced the
overall percentage of RPCs that continued to proliferate, we measured the proliferative fraction
(p-fraction) by exposing retinal explants to BrdU at the onset of 2DG treatment, and then
immunostaining for BrdU and Ki67, which labels all cycling cells. The p-fraction was calculated
as the ratio of Ki67$^+$ cells that were BrdU$^+$ (*i.e.,* %BrdU$^+$Ki67$^+$/Ki67$^+$ cells). The total numbers of
BrdU$^+$ and Ki67$^+$ cells declined in 2DG-treated explants, as did the overall p-fraction (Figure
3D).

A reduction in the p-fraction could indicate that RPCs had stopped cycling during the 24-
hr window of 2DG treatment, or that these cells had undergone apoptosis. To distinguish
between these possibilities, we first immunostained 2DG-treated retinal explants with VSX2,
which primarily labels RPCs at P0. 2DG treatment for 24 hr did not alter the total number of
VSX2$^+$ RPCs, even at the higher dose of 10 mM, despite the dramatic decline in proliferating

RPCs (Figure 3E). Furthermore, 2DG treatment did not elevate levels of apoptosis, as the number of cleaved-caspase 3 (CC3) expressing retinal cells remaining similar in 2DG-treated and control explants (Figure 3F). We then asked whether glycolytic inhibition impacted cellular differentiation, focusing on CRX-expressing photoreceptor precursors, which are the main cells generated at P0. At the highest 10 mM 2DG dose, the number of CRX$^+$ cells declined, indicative of a dose-dependent decrease in the number of photoreceptor precursors born (Figure 3G). Taken together, these data indicate that glycolytic inhibition suppresses RPC proliferation, and at higher doses, prevents RPCs from differentiating into photoreceptors. Stated differently, glycolysis is required to support RPC proliferation and photoreceptor differentiation.

Previous studies in *Xenopus* similarly found that RPCs rely mainly on glycolysis for energy production, however, instead of the demand for a constant supply of glucose, Xenopus RPCs depend on glycogen storage (Agathocleous et al., 2012). To test whether mouse RPCs similarly require stored glycogen, P0 retinal explants were cultured in the presence of 12.5 µM and 25 µM glycogen phosphorylase inhibitor (GPI) for 24 hr (Figure 3H), the latter corresponding to the same concentrations used in Xenopus retina (Agathocleous et al., 2012). In murine retinal explants, GPI treatment did not impact the number of RPCs that incorporated BrdU (Figure 3H). These data suggest that rather than depending on glycogen stores, murine RPCs depend on a constant supply of glucose to maintain proliferation, as shown in human retinal organoids (Takata et al., 2023).

Precocious rod differentiation and maturation in *cytoPFKB3* gain-of-function mice phenocopies *Pten*-cKO retinal features

We previously showed that at P7, *Pten*-cKO retinas are comprised of fewer differentiated rods and amacrine cells, while other cell types are not affected (Tachibana et al., 2016). Given the increase in glycolysis in *Pten*-cKO retinas observed in the current study, we asked whether metabolic reprogramming may be sufficient to bias RPC fate choice, thereby altering cellular composition. As a precedent, glycolytic flux alters neuromesodermal lineage selection in the chick tail bud (Oginuma et al., 2020) and in mouse mesoderm (Miyazawa et al., 2022). To determine whether increased glycolysis is a critical downstream effector pathway of *Pten* in retinal cell fate selection, we used a transgenic approach to elevate glycolytic flux in RPCs. Glycolytic flux is defined as the conversion of fructose 6-phosphate (F6P) to fructose-1,6-bisphosphate (FBP), which is catalyzed by phosphofructokinase (PFK1), and is the first rate-limiting, commitment step in glycolysis (Miyazawa et al., 2022) (Figure 4A). To promote glycolytic flux, we used a conditional gain-of-function (GOF) transgenic line driving the expression of a dominant active, cytoplasmic form of PFKB3 (cyto*PFKB3*) (Miyazawa et al., 2022). PFKB3 converts F6P to fructose-2,6-bisphosphate, which is a strong, allosteric activator of PFK1 (Shi et al., 2017) (Figure 4A). To overexpress cyto*PFKB3* in RPCs, we removed the floxed stop cassette using a *Pax6-Cre* driver to create a cyto*PFKB3* GOF model (Figure 4B). Of note, the same *Pax6-Cre* driver was employed to generate *Pten*-cKOs used in this study. To confirm that cyto*PFKB3*-GOF retinas undergo increased glycolytic flux, we measured levels of secreted lactate as a proxy measure using a colorimetric assay. We observed an overall increase in lactate levels in P0 cyto*PFKB3*-GOF retinas (Figure 4C).

Having validated the GOF model, we next asked whether elevating cyto*PFKB3* expression in RPCs impacted the timing of retinal cell differentiation using a birthdating assay.

BrdU was administered to pregnant females at E12.5 and pups were sacrificed at P7. In wild-type retinas, BrdU$^+$ cells were mainly distributed in the GCL, where newborn ganglion cells and displaced amacrine cells reside, and in the INL, where amacrine cells and horizontal cells are located (Figure 4D,E). Fewer BrdU$^+$ cells labeled at E12.5 were present in the P7-ONL, with these early-born ONL cells primarily including cones in wild-type retinas (Figure 4D,E). In cyto*PFKB3*-GOF retinas, BrdU$^+$ cells were also distributed amongst the three layers, but BrdU$^+$ cells were more abundant in the ONL, where photoreceptors reside, with a concomitant reduction in the INL (Figure 4D,E). The shift in distribution of E12.5-labeled, BrdU$^+$ cells phenocopies the altered temporal differentiation observed in *Pten*-cKO retinas (Tachibana et al., 2016).

The accelerated differentiation of ONL cells in cyto*PFKB3*-GOF retinas prompted us to ask whether photoreceptor maturation was similarly hastened, focusing on OS formation as a readout. While most differentiated cells use OXPHOS for energy production, photoreceptors are an important exception, as these metabolically demanding cells require glycolysis to maintain OSs, which undergo diurnal turnover (Chinchore et al., 2017). To examine OS formation, we immunostained P7 wild-type and cyto*PFKB3*-GOF retinas with rhodopsin (Figure 4F). Visually, photoreceptor OS above the ONL, which are labeled with rhodopsin, were larger in P7 cyto*PFKB3*-GOF retinas, as confirmed by a measurement of the OS area (Figure 4F).

To determine whether rod photoreceptor OSs similarly mature precociously in *Pten*-cKO retinas, we first examined the P0 transcriptomic data for OS-enriched genes (Datta et al., 2015). We identified several OS genes that were up-regulated in P0 *Pten*-cKO retinas, although not all, as several OS genes were also down-regulated (Figure 4G). To assess OS maturation morphologicaly, we immunostained P7 retinas with rhodopsin, revealing a similar increase in the rhodopsin-labeled OS area in *Pten*-cKOs (Figure 4I). Finally, to investigate the role of glucose metabolism in accelerating the rate of rod photoreceptor maturation, we inhibited glycolysis during the early postnatal window by *in vivo* administration of 2DG, which was administered daily from P0 to P7 (Figure 4H,I). Strikingly, 2DG treatment blocked the precocious maturation of rod photoreceptor OSs in *Pten*-cKO retinas, which returned to wild-type sizes (Figure 4I). Taken together, these data implicate glucose metabolism and glycolysis as an important driver of photoreceptor differentiation and OS maturation.

Reducing pHi phenocopies the inhibitory effects of a glycolytic block on RPC proliferation and differentiation

Glycolysis is not an energy-efficient metabolic pathway as cells produce 2 ATP/glucose molecule versus 30-38 ATP/glucose when using OXPHOS (Touahri et al., 2024). However, cells rely on glycolysis for reasons other than energy expenditure. For instance, lactate is a metabolic byproduct that is shuttled out of the cell along with one H$^+$ ion by lactate/H$^+$ symporters (Slc16a group proteins) when glycolytic activity is high, effectively increasing intracellular pH (pHi) (Figure 5A). Notably, glycolysis-driven increases in pHi are the central driver of cell fate choice selection in the chick neuromesodermal lineage (Oginuma et al., 2020). We found *Slc16a* family lactate/H$^+$ symporters are elevated in *Pten*^{cKO} retinas (Figure 2E), suggesting that more protons may be extruded to increase pHi. To address whether lactate/H$^+$ symporters control RPC proliferation, we incubated wild-type P0 explants with 5mM α-cyano-4-hydroxycinnamate (CNCn), an inhibitor of monocarboxylate transporters, including the Slc16a-family symporters,

for 24 hr (Figure 5B). The impact of CNCn should block the export of lactate into the
extracellular space, effectively lowering pHi and further decreasing glycolysis. To determine
whether RPC proliferation was impacted by CNCn treatment, explants were incubated with
BrdU 30 min before harvesting. We observed a decrease in the number of BrdU$^+$ proliferating
RPCs in CNCn-treated retinal explants compared to controls (Figure 5C). This decline in RPC
proliferation mirrored the effect of inhibiting glycolysis (Figure 3C). Thus, Slc16a-family
symporters play a role in regulating RPC proliferation in the retina.

In keeping with the idea that pH levels influence cell fate selection, a previous study
found that neuromesodermal progenitors in chick tailbud explants cultured in low pH media
undergo cell cycle exit and lineage selection is biased towards neural rather than mesodermal
fates (Oginuma et al., 2020). Importantly, PKM2 is the rate-limiting enzyme for glycolysis, and
at low pH, PKM2 aggregates in reversible amyloids that are inactive (Cereghetti et al., 2024). To
assess the role of altered pHi on cell fate selection in the retina, we grew retinal explants in
media buffered at pH 6.5 (acidic), pH 7.4 (neutral), or pH 8.0 (basic). Increased glycolysis,
leading to more H$^+$ extrusion from the cell and an increase in pHi was modeled by pH 8.0, while
decreased glycolysis, leading to less H$^+$ extrusion and a lower pHi, was modeled by pH 6.5. To
assess the impact of pHi changes on RPC proliferation, P0 retinal explants were cultured in
media buffered to different pH levels, with BrdU added for 30 min and at the end of the 24-hr
culture period. More RPCs were BrdU$^+$ in pH 8.0 media compared to neutral pH 7.4 media,
consistent with the pro-proliferative effect of increased glycolysis (Figure 5D). Conversely, in
media buffered to pH 6.5, the number of BrdU$^+$ proliferating RPCs declined (Figure 5D).

To determine whether pH changes alter the overall percentage of RPCs that continue to
proliferate, we measured the p-fraction by exposing retinal explants to BrdU at the onset of pH
adjustments, and then calculating the p-fraction as the ratio of Ki67$^+$ cells that were BrdU$^+$. We
found a pH-dependent increase in the number of BrdU$^+$ RPCs and in the p-fraction in retinal
explants cultured in pH 8.0 compared to pH 7.4 (neutral pH control) media (Figure 5E). We also
observed a corresponding increase in VSX2$^+$ RPCs in pH 8.0 media (Figure 5F), and more RPCs
differentiated into CRX$^+$ photoreceptor precursors (Figure 5H). In contrast, in retinal explants
cultured in pH 6.5 media, fewer RPCs entered S-phase as evidenced by the decline in BrdU$^+$
RPCs and lower p-fraction (Figure 5E). However, there were more VSX2$^+$ RPCs in retinal
explants grown in pH 6.5 versus pH 7.4 media (Figure 5F), with no effect on cell death evident
as assessed by cleaved-caspase 3$^+$ cell counts (Figure 5G), likely because fewer of these RPCs
differentiated into CRX$^+$ photoreceptor precursors (Figure 5H). Thus, pH has a dramatic effect
on the decision by RPCs to proliferate versus differentiate, with higher pH more conducive to
rapid, self-renewing, asymmetric divisions (P/D) that generate an RPC and a neuron.

Tissues naturally have pHi and differentiation gradients – for instance, there is an anterior
(low pHi, more differentiated cells) to posterior (high pHi, more neuromesodermal progenitor
cells) gradient in neuromesodermal progenitors in the embryonic chick tailbud (Oginuma et al.,
2020). Given the importance of pH to control RPC proliferation and differentiation dynamics,
and since not all RPCs differentiate at any given time, we asked whether there was a dynamic
representation of pH within RPCs within the developing retina. To test this assumption, we
electroporated P3 retinal explants with pCAGG-pHluorin-IRES2-tdTomato, using tdTomato to
label transfected cells and pHluorin, a ratiometric pH sensor with a 488-nm activation spectrum
in neutral pH. As expected, the 488-nm signal was variable across RPCs that had similar
tdTomato levels (Figure 5I). Taken together, this data is consistent with the idea that pH varies

within RPCs, correlating with the propensity of some RPCs to continue to proliferate while
others to differentiate.

Canonical Wnt signaling is active in neurogenic RPCs and controlled by glycolysis

Our finding that glycolysis might be a central driver of RPC fate selection, in part
through the control of pHi, prompted the question of how these biochemical processes might
impact cell fate selection. To glean further insights, we revisited our bulk RNA-seq data set from
P0 *Pten*-cKO retinas and performed a PANTHER (protein analysis through evolutionary
relationships) classification analysis of DEGs (Figure 6-figure supplement 1). As expected,
glycolysis was amongst the up-regulated pathways, but the most up-regulated pathway in P0
Pten-cKO retinas was Wnt signaling (Figure 6-figure supplement 1). Wnts bind to frizzled (Fz)
and low-density lipoprotein receptor-related protein receptors (LRPs), which induces β–catenin
translocation to the nucleus, where it forms an active transcriptional complex with T-cell-specific
transcription factor (TCF)/lymphoid enhancer-binding factor (LEF) transcription factors (Figure
6A). Prior studies had implicated canonical Wnt signaling in maintaining an undifferentiated
RPC state, especially in the peripheral margin at early developmental stages (Ouchi et al., 2011).
However, mining scRNA-seq data from E11 to P14 retinas (Clark et al., 2019) revealed that Wnt
signaling may be active throughout retinal development, with transcripts for *Wnt7b* and *Lef1,*
which is transcribed in response to canonical Wnt signaling (Schmidt et al., 2000), detected in
RPCs at all developmental stages (Figure 6B). Furthermore, we noted that *Dkk*, a Wnt inhibitor,
is only expressed in pre-neurogenic RPCs, and not in RPCs in the early and late neurogenic
periods, suggesting that Wnt signaling may not be active prior to the onset of neurogenesis
(Figure 6B). We thus explored whether Wnt signaling was regulated by glycolysis to play a role
in RPC differentiation.

Components of the Wnt signaling pathway that were upregulated in P0 *Pten*-cKO retinas
included *Dvl3*, an inhibitor of the β-catenin destruction complex, *Apc* and *Gsk3b*, two
components of the destruction complex, and *Tcf4* and *Crebbp*, a downstream effector of Wnt
signaling and its co-activator, respectively (Figure 6C). These data were consistent with our
previous demonstration that canonical Wnt signaling levels are elevated in *Pten*-cKO retinas, as
assessed by increased expression of non-phosphorylated (active) β-catenin (Touahri et al., 2024).
However, unlike in the peripheral retina of *Ctnnb1*-cKOs (encoding for β-catenin), in which the
neurogenic inhibitor *Id3* is activated by Wnt signaling in the periphery to maintain RPCs in an
immature, undifferentiated state (Ouchi et al., 2011), we found that *Id3* is down-regulated in P0
Pten-cKO retinas (Figure 6C), potentially allowing differentiation to proceed unimpeded.

Finally, to establish whether Wnt signaling was indeed regulated by glycolytic activity,
we investigated β-catenin levels in explants treated with 2DG or grown in different pH media. β-
catenin levels declined upon glycolysis inhibition in 2DG treated explants (Figure 6D), and at pH
6.5, a proxy for low glycolysis (Figure 6E). Thus, canonical Wnt signaling is elevated in P0
Pten-cKO retinas (Touahri et al., 2024), in which glycolysis is elevated, and reduced in
conditions in which glycolysis is inhibited.

Wnt signaling controls rod photoreceptor differentiation and maturation

We next asked whether inhibiting Wnt signaling would phenocopy the effects of reducing
glycolysis on RPC proliferation and photoreceptor differentiation. For this purpose, we treated
P0 wild-type CD1 retinal explants with 5 µM or 10 µM FH535, a pharmacological inhibitor of
Wnt/β-catenin signaling (Handeli & Simon, 2008), for 24 hr. To label proliferating RPCs, BrdU
was added 30 min before harvesting similar to previous experiments. FH535 treated retinas
showed a significant decrease in the number of BrdU$^+$ RPCs (Figure 7A) and a concomitant
decrease in the number of CRX$^+$ photoreceptor precursors (Figure 7B) without impacting
apoptosis (Figure 7C). To further study the role of Wnt signaling in photoreceptor maturation,
we crossed a floxed allele of *Ctnnb1*, encoding for β-catenin, with a *Pax6-Cre* driver, which we
previously confirmed leads to β-catenin loss in P14 *Ctnnb1*-cKO retinas (Touahri et al., 2024).
P14 wild-type and *Ctnnb1*-cKO retinal sections were immunolabeled with rhodopsin, showing a
clear reduction in OS area upon the inhibition of Wnt signaling (Figure 7D).

Finally, in chick neuromesodermal progenitors, high glycolytic activity or elevated pHi
promotes the non-enzymatic acetylation of β-catenin, which promotes mesodermal at the
expense of neural cell fate selection (Oginuma et al., 2020). To force protein acetylation,
including of β-catenin, cells can be grown in sodium acetate. We observed that the exposure of
retinal explants to 5-, 10-, or 20 mM sodium acetate increased the percentage of BrdU$^+$
proliferating RPCs (Figure 7E). Thus, the forced activation of β-catenin acetylation is sufficient
to promote RPC proliferation, mimicking the early impact of *Pten* loss/high glycolytic activity in
RPCs (Tachibana et al., 2016). Taken together, our study identifies an unexplored pathway in
which PTEN controls RPC proliferation and rod differentiation and maturation via modulating
glycolysis. Glycolysis in turn controls proliferation and differentiation through modulating pHi
that creates a favorable environment for Wnt signaling activation (Figure 7F).

DISCUSSION

The timing of RPC differentiation and neural subtype specification must be precisely
coordinated so that the correct types of retinal neurons and glial cells are born at appropriate
times and in their proper numbers during development. In *Pten*-cKO retinas, RPCs proliferate
and differentiate on an accelerated timeline (Jo et al., 2012; Sakagami et al., 2012; Tachibana et
al., 2016), resulting in the precocious depletion of proliferating RPCs (this study). Ultimately, the
changes in RPC proliferation dynamics culminate in the production of fewer amacrine cells and
rod photoreceptors populating the P7 *Pten*-cKO retina (Tachibana et al., 2016; Touahri et al.,
2024). To understand how *Pten* controls RPC fate decisions, we first used a transcriptomic
approach, revealing an increase in glycolytic gene expression and activity in *Pten*-cKO retinas.
Consistent with a role for glycolysis in controlling RPC proliferation and photoreceptor cell
differentiation, both were inhibited by 2DG, a pharmacological inhibitor of glycolysis.
Conversely, the promotion of glycolytic flux in RPCs using cyto*PFKB3* GOF transgenic mice
accelerated photoreceptor differentiation, including the enhanced maturation of rod OSs, an
effect phenocopied in *Pten*-cKO retinas. Since elevated glycolytic activity shuttles more
lactate/H$^+$ out of the cell to increase intracellular pH (pHi), we cultured retinal explants in media
buffered to higher pH levels, which promoted RPC proliferation and accelerated photoreceptor
differentiation. Finally, we linked glycolysis and pHi changes to the activation of Wnt signaling,
which we found is required to promote RPC proliferation, photoreceptor differentiation, and OS
maturation. Taken together, we have uncovered a novel molecular axis controlling RPC fate

decisions in the retina that begins with *Pten*, a signal transduction molecule, the loss of which
elevates glycolytic activity, pHi, and Wnt signaling (Figure 7E).

Similar to our findings in mice, glycolysis is the predominant mode of ATP production in
proliferating *Xenopus* and zebrafish RPCs (Agathocleous et al., 2012). However, in contrast to
the results of our study, treatment of Xenopus retinas with 2DG, a glucose inhibitor, does not
impact ATP or lactate production, whereas GPI-mediated inhibition of access to glycogen stores
reduces energy production (Agathocleous et al., 2012). Thus, Xenopus RPCs rely on glycogen
storage to fuel glycolysis, whereas we found that in mouse retina, a constant glucose supply is
required to fuel glycolysis and support RPC proliferation. Consistent with our data, in mice
carrying mutations in *Glut1,* a glucose transporter, or *Ldha*, a glycolytic enzyme that converts
pyruvate to lactate, RPC proliferation and expansion of the optic vesicle are inhibited (Takata et
al., 2023). Human RPCs also use glycolysis as revealed by the conversion of ^{13}C-glucose to
lactate, a glycolytic intermediate (Takata et al., 2023). Moreover, the inhibition of glucose
catabolism by 2DG blocked RPC proliferation and eye morphogenesis in human retinal
organoids (Takata et al., 2023). Intriguingly, in this organoid study, RPC identity markers,
including RAX, and SIX3, were also suppressed by 2DG, a phenotype attributed to lactate
depletion, which indicates that glycolysis is also critical for progenitor cell identity (Takata et al.,
2023). One possibility is that the "energy budget" of a cell, dictated by adenosine triphosphate
(ATP) and precursor metabolite levels, controls levels of transcription of retinal cell identity
genes (Carthew, 2021). Glycolytic metabolites can also impact gene transcription in other ways.
For example, lactate, a metabolic byproduct of glycolysis, inhibits histone deacetylase (HDAC)
activity to acetylate H3K27ac and activate eye development genes in retinal organoids (Takata et
al., 2023). Indeed, the addition of lactate to retinal organoids induced broad transcriptional
changes, including an upregulation of genes involved in eye morphogenesis (Takata et al., 2023).
Mechanistically, lactate effects on the transcription of eye field markers were attributed to the
inhibition of HDACs, which normally inhibit gene expression via histone deacetylation (Takata
et al., 2023). In the future, we can further assess the impact of 2DG and other metabolic
inhibitors on RPC differentiation, focusing on additional retinal cell types, such as bipolar,
horizontal and amacrine cell interneurons, and Müller glia.

A proxy measure for glycolytic activity are the levels of sentinel metabolites
(Kochanowski et al., 2013; Miyazawa et al., 2022; Oginuma et al., 2020; Peeters et al., 2017;
Zhang et al., 2017). In chick embryonic tailbuds (Oginuma et al., 2020) and the murine
presomitic mesoderm (Miyazawa et al., 2022), FBP was identified as a sentinel metabolite since
its levels positively correlate with glycolytic activity. However, while FBP has been ascribed a
major role in controlling mouse embryonic mesoderm development (Miyazawa et al., 2022),
neuromesodermal fate selection in the chick embryonic tailbud is controlled by elevated pHi
induced by high glycolytic activity (Oginuma et al., 2020). In the chick tailbud, high pHi creates
an environment that activates Wnt signaling through non-enzymatic acetylation of β-catenin
(Oginuma et al., 2020). Thus, while phosphorylated and non-phosphorylated β-catenin levels do
not vary, K49 β-catenin acetylation is reduced at low pHi (Oginuma et al., 2020). The onset of
K49 β-catenin acetylation is associated with a switch in cell fate choice from neural to
mesodermal in the chick tailbud (Oginuma et al., 2020). In contrast, in adult cardiomyocytes,
when *Pkm*, a rate-limiting glycolytic enzyme, is mutated, β-catenin can more efficiently shuttle
to the nucleus to activate Wnt-signaling and promote cardiomyocyte proliferation (Hauck et al.,
2021). In cardiomyocytes lacking *Pkm*, transcriptional targets of Wnt signaling, including *Axin2,*

Ccnd1, Myc, Sox2 and *Tnnt3,* are elevated, and β-catenin protein remains in the cytoplasm,
rather than undergoing nuclear translocation (Hauck et al., 2021). Similarly, in a study performed
in cancer cells, high pH leads to increased expression of *Ccnd1*, a β-catenin target gene, and
increases proliferation rates (Koch et al., 2020). These findings are consistent with our
demonstration that β-catenin levels are stabilized at pH 8, and RPC proliferation is enhanced.
Finally, in a separate study performed in cancer cells, acidification induced by metformin
indirectly suppresses Wnt signaling by activating the DDIT3 transcriptional repressor (Melnik et
al., 2018), consistent with our data showing low pH suppresses β-catenin stability. Melnik et al.
(2018) also used Mcl inhibitors, as we did in our study, and showed that this treatment blocks
Wnt signaling. While we did not look at the impact of CNCn on Wnt signaling, we did see a
decline in proliferation, as expected if Wnt levels are low.

Our finding that Wnt signaling is required to maintain RPC proliferation and drive
photoreceptor differentiation is contrary to prior studies that ascribed a role to *Ctnnb1* in
maintaining RPCs in an immature, uncommitted state without affecting proliferation (Ouchi et
al., 2011). A major difference is that Ouchi et al. (2011) found that *Id3*, a neurogenic inhibitor, is
upregulated in *Ctnnb1* cKO retinas, whereas we found that *Id3* expression levels decline in *Pten*-
cKO retinas. It may therefore be that the precocious photoreceptor differentiation we observed in
the absence of *Pten* occurs due to the reduction in inhibitory *Id3* levels. There may also be a
biphasic role for Wnt signaling, as has been observed during neocortical development, where
canonical Wnt signaling first induces the symmetric proliferative divisions of neural progenitor
cells and later induces differentiation (Harrison-Uy & Pleasure, 2012). Finally, the ectopic
expression of *Wnt2b* inhibits neuronal differentiation in the chick retina (Kubo et al., 2005),
phenocopying the postnatal *Pten*-cKO retinal phenotype observed in this study, in which Wnt
signaling is also elevated. However, while ectopic *Wnt2b* expression suppresses chick RPC
differentiation by inhibiting the expression of proneural genes, we did not observe a significant
impact on Notch signaling or proneural gene expression in *Pten*-cKO retinas (data not shown).
Thus, the gain of Wnt signaling in *Pten*-cKO retinas impacts RPC proliferation and
differentiation possibly in a proneural gene-independent manner.

The link between glycolysis and Wnt signaling may be species- and lineage-specific. For
instance, in mouse embryos, Miyazawa et al., found that increasing glycolysis in the presomitic
mesoderm inhibits Wnt signaling (Miyazawa et al., 2022). Furthermore, in a study performed in
Madin Darby Canine Kidney (MDCK) cells, higher pH levels were shown to decrease β-catenin
levels in the cytoplasm, nucleus and junctional complexes (Czowski & White, 2024). In this
study, the authors altered pH using inhibitors for a sodium-proton exchanger and a sodium
bicarbonate transporter, in contrast to the Oginuma et al. (2020) study, which instead used the
ionophores nigericin and valinomycin to equilibrate intracellular pHi to media pH. Consistent
with the idea that there is some species specificity, in human retinal organoids, lactate itself was
shown to alter optic vesicle bud gene expression, whereas pH did not appear to be an important
driver of cell fate decisions (Takata et al., 2023). In contrast, in the mouse retina, the GPR81
receptor for lactate is expressed at the highest levels in ganglion cells in which it is required to
promote axon growth, with only low, possibly background expression levels in RPCs and
photoreceptors (Laroche et al., 2021). In the future, to more comprehensively examine the link
between *Pten* loss, glycolytic activity, pHi and Wnt signaling, we could examine levels of
phosphorylated, non-phosphorylated and K49 acetylated β-catenin after each manipulation (*i.e.,*
Pten loss, pH manipulations, CNCn treatment, glycolysis inhibition, acetate treatments). By

collecting CD133[+] MACS-enriched RPCs from the retinal explants, we can add cell type and
stage specificity to our analysis. Finally, the use of qPCR to examine Wnt signaling genes, such
as *Axin2, Ccnd1, Myc, Sox2* and *Tnnt3*, would provide further support for the impact of
glycolysis and pH on this signaling pathway. Another caveat to our study is that metabolism
changes ex vivo versus in vivo, and thus, in the future, in vivo studies can be performed to assess
metabolic changes.

Our finding that *Pten* loss drives photoreceptor differentiation and OS maturation was an
unexpected fate bias given that during development, *Pten* is expressed in multipotent RPCs
(Tachibana et al., 2016) that give rise to all retinal cells in a defined temporal sequence (Javed &
Cayouette, 2017). RPCs that are biased to a generic photoreceptor fate express the transcription
factor (TF) Olig2; if these cells later express the TF Nrl, they become rods, if not, they become
cones (Hafler et al., 2012; Javed & Cayouette, 2017). In *Pten*-cKO retinas, more RPCs become
photoreceptors instead of differentiating into other retinal cell types at early developmental
stages (Tachibana et al., 2016), but this phenotype is not likely to be dependent on Olig2, since
Olig2 is expressed at normal levels from the RNA-seq study performed herein. It is possible that
glycolytic inhibition with 2DG slows down the development and production of most newly
differentiated cells rather than specifically affecting photoreceptor differentiation, which we
could assess in the future. Nevertheless, the finding that *Pten* loss elicits a photoreceptor bias in
early RPCs could have widespread applications in targeting uncurable retinal diseases. Notably,
the pharmacological inhibition of PTEN has been used in pre-clinical studies in lung, muscle,
and nervous systems for regenerative purposes (Borges et al., 2020; Knafo & Esteban, 2017),
including in the retina, to promote ganglion cell axonogenesis (Park et al., 2008).

In summary, we have revealed that elevated glycolysis is a key contributor to the RPC
fate alterations observed in *Pten*-cKO retinas. In particular, we have found that glycolytic flux is
elevated in *Pten*-cKO retinas, which modulates both pHi and Wnt signaling to control the timing
of RPC proliferation and differentiation.

MATERIALS AND METHODS

Mice. All animal procedures were approved by the Sunnybrook Research Institute Animal Care
Committee (16-606) in agreement with the Guidelines of the Canadian Council of Animal Care
(CCAC). The following transgenic animal lines were used from Jackson Laboratory: *Pten[fl]* allele
(Backman et al., 2001) (B6.129S4-*Pten[tm1Hwu]*/J. Strain #: 006440, RRID:IMSR_JAX:006440),
Ctnnb1[fl]: B6(Cg)-Ctnnb1tm1Knw/J. RRID:IMSR_JAX:022775) and *Pax6::Cre* driver
(Marquardt et al., 2001) (STOCK Tg(Pax6-GFP/cre)1Rilm/J. Strain #:024578.
RRID:IMSR_JAX:024578. Common Name: P0-3.9GFPCre) and Ctnnb1[fl]: B6(Cg)-
Ctnnb1[tm1Knw]/J. (RRID:IMSR_JAX:022775). For glycolysis gain of function studies,
cyto*PFKB3*- mice (EMBL, Germany) (Miyazawa et al., 2022) were crossed with a *Pax6::Cre*
driver to generate cyto*PFKB3*-GOF transgenic mice. PCR genotyping was performed as
described by Jax for commercial lines and as described for the cyto*PFKB3* allele (Miyazawa et
al., 2022). All lines were maintained on a C57BL/6J background through backcrossing (Strain
#:000664. RRID:IMSR_JAX:000664. Common Name: B6). Animal explants were performed
with CD1 mice (Charles River, IMSR_CRL:022). The day of the vaginal plug was considered to
be embryonic day E0.5 for timed pregnancies.

Bulk RNAseq. P0 *Pten*-cKO and wild-type control eyes were dissected in a clean petri dish containing Dulbecco's phosphate buffered saline (DPBS). A pair of super-fine tweezers (#5, Fine Scientific Tools, Canada) was used to remove the cornea, iris, sclera and retinal pigment epithelium. Retinas were homogenized using TRIzol (Thermo Fisher Scientific; #15596-026) according to the manufacturer's protocol. RNA was then purified using an RNAeasy minikit (74104, Qiagen). Eluted RNA quality and concentration was assessed using a NanoDrop. Samples with the highest purity (260/280 ratio = 2.0) were used for RNA sequencing (RNAseq) experiments. Five *Pten* cKO and four wild-type samples were sent to the University of Lethbridge, Alberta for sequencing. Illumina NextSeq 500 performed sequencing using 75bp Single-End reads. A NEBNext Ultra II Directional RNA Library Prep Kit was used to construct a library containing read counts, and was compared to a Mouse GRCM38 reference genome. Differentially expressed genes (DEGs) were identified using the DESeq1 1.28.1 package. An adjusted p-value (padj) less than 0.05 for any gene was considered a DEG (Wald test, Benjamini-Hickberg correction for multiple comparisons). DEGs were visualized by Volcano plot (R package: EnhancedVolcano 1.6.0) and heatmap (R package: gplots 3.0.3, function heatmap 2). Gene Ontology (GO) terms for Biological Processes and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways were assayed using the DEG up- and down-regulated DEGs (Pathview 1.28.0 package).

In vivo injections. For birthdating and proliferation studies, animals were injected with BrdU at 10mg/kg intraperitoneally at E12.5 and then harvested at P7. For 2DG *in vivo* experiments, newborn pups were injected with 2-deoxy-d-glucose (2DG) intraperitoneally (30mg/Kg, Sigma Aldrich, Oakville, Canada) daily starting at P0 until P7.

Tissue processing and immunostaining. Animals were sacrificed using CO_2 euthanasia. Eyes were dissected and fixed in 4% paraformaldehyde (PFA) overnight at 4ºC. Fixed eyes were rinsed with PBS and incubated in 20% sucrose overnight. Eyes were then embedded in optical cutting temperature (O.C.T™) compound (Tissue-Tek®, Sakura Finetek U.S.A. Inc., Torrance, CA) and frozen on dry ice before being sectioned in a series of 10uM slices using a Leica CM3050s cryostat (Leica Biosystems, Buffalo Grove, IL, USA). Sections were mounted on Fisherbrand™ Superfrost™ Plus slides (Thermo Fisher Scientific, Markham, ON). Sections were blocked for 1 hour in 10% normal horse serum in 1X PBS/0.1% Triton X-100 (PBST). Primary antibodies were diluted in a blocking solution and incubated at 4ºC overnight. Primary antibodies included: BrdU (1:400, ab6326, Abcam), VSX2 (1:200, sc-365519, Santa Cruz), Ki67 (1:400, ab16667, Abcam), cleaved caspase 3 (CC3; 1:400, ab2302, Abcam), Rhodopsin (1:400, MAB 5356, Millipore), PAX6 (1:400, #PRB-278P; Covance Research), PTEN (1:400, 9559S, Cell Signaling) and CRX (1:400, NBP2-15964. Novus Biologicals). Slides were washed 3 x 10 min in PBST and then incubated in secondary antibodies diluted in PBST for 1 hour. Secondary antibodies were conjugated to Alexa568 (1:500, Molecular Probes), Alexa488 (1:500, Molecular Probes), or Alexa647 (1:500, Molecular Probes). Sections were washed 3 x 10 min washes in PBST. Sections were counterstained with 4',6-diamidino-2-phenylindole (DAPI, Invitrogen, D1306) and coverslipped in Aqua-Poly/Mount (Polysciences #18606).

Retinal explants. For retinal explants, P0 wild-type CD1 mice pups were sacrificed by decapitation. Eyes were dissected in ice-cold PBS. Corneas were removed first, followed by the removal of sclera, iris, and lens. Retinal cups were then mounted on Cytiva Whatman™ 90 mm Nuclepore™ Polycarbonate Track-Etched Membranes (Catalog Number 09920022, Cytiva, Canada). Four cuts were made to flatten cups on the membranes using TMS101 Gills-Vannas

Scissors (SKU: TMS101, Titan Medical, Coral Gables, FL, USA). Retinal mounted membranes
were then transferred to 24 well plates (Corning® Costar® TC-Treated Multiple Well Plates,
Catalog Number: CLS3524, Millipore Sigma) filled with 1 mL of retinal explant media (50%
DMEM, 25% HBSS, 25% heat-inactivated horse serum, 200 µM L-glutamine, 0.6 mM HEPES,
1% Pen-Strep). Retinas were then incubated at 37ºC, 5% CO_2. At the experimental endpoint (as
indicated), explants were fixed at room temperature with 4% PFA for 15 min, rinsed with DEPC-
treated PBS and incubated in 20% DEPC-Sucrose overnight. Explants were then mounted in
OCT on dry ice and cryosectioned at 10 µM as described above.

Retinal explant drug treatments. For BrdU labeling, 5 µL of 10 mg/mL BrdU was added to the
retinal cell explant media for the time period described. All inhibitors were incubated with retinal
explants for 24 hours. 2DG (D3179-1G, Sigma Aldrich, Canada) was diluted in PBS and added
to retinal explant media to achieve 5 mM and 10 mM final concentrations. Glycogen
phosphorylase inhibitor (GPI) (361515-1MG, Sigma Aldrich, Canada) was diluted in DMSO and
added to the retinal explant media at a final concentration of 12.5 µM or 25 µM. α-cyano-4-
hydroxy-cannamic acid (CNCn; C2020-10G; Sigma Aldrich, Canada) was diluted in explant
media and added to explant media at a final concentration of 5 mM. For pH experiments, pH was
adjusted after incubating the media in cell culture incubator for 1 hour using hydrochloric acid or
sodium hydroxide to reach a pH of 6.5 and 8.0, respectively. FH535 was diluted in DMSO and
added to the retinal explant media at 5mM and 10mM concentrations for 24 hours (108409,
Millipore Sigma, Canada). For acetate explants, retinas were incubated with sodium acetate at a
concentration of 5 mM, 10 mM or 20 mM diluted in PBS for 48 hours (S2889, Millipore Sigma,
Canada).

Retinal explant electroporation. P2 wild-type retinal explants were electroporated with pCAGG-
pHluorin-IRES2-tdTomato obtained from Olivier Pourquié (Oginuma et al., 2020) as described
(Tachibana et al., 2016). Briefly, retinas were placed in 2 mm gap cuvettes (VWR International)
with 30ul of DNA at 0.5 µg/ µl. Retinas were then electroporated using an ECM830 pulse
generator (BTX Harvard Apparatus) using five square 20 V pulses of 50 ms duration, separated
by 950 ms intervals. After electroporation, retinas were cultured on Nuclepore™ Polycarbonate
Track-Etched Membranes in retinal explant media at 37ºC, 5% CO_2.

qPCR. TRIzol® RNA Isolation Reagent (Thermo Fisher Scientific; #15596-026) was used to
extract RNA according to the manufacturer's instructions. cDNA was synthesized from 0.5 µg
RNA using an RT^2 first-strand kit (Qiagen, #330401) according to the manufacturer's
instructions. qPCR was performed using an RT^2 SYBR® Green PCR Master Mix (Qiagen;
#330500) as described by the manufacturer, with a CFX384 cycler (Biorad Laboratories,
Canada). The following primers were used: *Eno1* (PPM04408B, Qiagen), *Hk1* (PPM05501A,
Qiagen), *Pgk1* (PPM03700A, Qiagen), *Slc16a3* (PPM27328A, Qiagen) and normalized to
housekeeping genes *Hprt* (PPM03559F, Qiagen), *B2m* (PPM03562A, Qiagen), and *Mapk1*
(PPM03571E, Qiagen).

Western blotting. For western blot, retinal cups were dissected on ice and both retinas of the
same animal were pooled together. Retinas were lysed in NP-40 lysis buffer (0.05 M Tris, pH
7.5, 0.15 M NaCl, 1% NP-40, 0.001 M EDTA) with protease (1X protease inhibitor complete, 1
mM PMSF), proteasome (MG132 at 0.05 mM) and phosphatase (50 mM NaF, 1 mM NaOV)
inhibitors. Protein amounts were quantified with a Micro BCA™ Protein Assay Kit
(ThermoFisher Scientific, #23235) following the manufacturer's instructions. 10 µg of lysate
from whole cells or tissue was run on 10% SDS-PAGE gels for western blot analysis. Protein

was transferred to PVDF membrane at 80V for 1 hour. PVDF membranes were then blocked in
5% skim milk powder in tris-buffered saline with 0.1% tween 20 (TBST) for 1 hour at room
temperature. Blots were incubated overnight at 4ºC in a blocking solution with non-
phosphorylated β-Catenin (1:1000, 8814, Cell Signalling) followed by β-actin (1:5000, ab8227,
Abcam). Blots were washed 3 x 10 min in TBST before incubating in secondary antibodies,
including either Goat Anti-Rabbit IgG (H+L)-HRP Conjugate (1/50,000; Bio-Rad #1721019 or
Cell Signaling #7074) or Goat Anti-Mouse IgG (H+L)-HRP Conjugate (1/50,000; Bio-Rad
#1721011). A chemiluminescent signal was obtained from the blots using (ECL Prime Luminor
Enhancer Solution, Cytiva, Canada) and the blot was developed using a ChemiDoc System (Bio-
Rad Laboratories, Canada). Densitometries were calculated using ImageJ (Schneider et al.,
2012), and normalized values (over ß-actin) were plotted.

scRNA-seq analysis. 10x scRNA-seq data of mouse developing retina was obtained from
GSE118614 (Clark et al., 2019). Further processing and analyses were performed with the Seurat
v.3.2.3 R package (Butler et al., 2018). Low-quality cells were excluded by filtering out cells
with fewer than 500 detected genes and cells with mitochondrial RNA more than 5%. The data
was then transformed by the SCTransform function while regressing out the variance due to
mitochondrial RNAs. Clustering was performed by the RunPCA, FindNeighbors, and
FindClusters functions using the first 30 principal components. The 2D projection of the
clustering was carried out by the RunUMAP function. The annotation of cell type to each cluster
was performed by using the same set of markers as in (Clark et al., 2019). Expression of selected
genes was plotted using the FeaturePlot function.

Seahorse assay. P0 *Pten*-cKO and wild-type control pups were sacrificed, and retinal cups were
dissected. Both retinas from the same animal were pooled together in one tube and dissociated
using a Papain kit according to manufacture protocol (Papain Dissociation System, Worthington
Biochemical Corporation, USA). Dissociated cells of each animal were then plated in a 6-well
plate coated with Poly-D-Lysine (10 mg/mL) (Corning, 354210)/Laminin (Corning, 354232)
(2.5 µg/mL) (Sarstedt, Germany). Cells were cultured for 5 days then transferred to Seahorse 96-
well plate at a density of 40,000/well. A Seahorse Mito stress test was run according to the
manufacture protocol. Seahorse basal media was supplemented with Oligomycin, FCCP, R/A at
the indicated time points (Seahorse XF Mito Stress Test Kit, 103015-100, Agilent, USA).
Readings were then normalized to protein concentration/well measured using the Micro BCA™
Protein Assay Kit.

Lactate assay. To measure lactate levels, P0 wild-type, *Pten*-cKO or cyto*PFKFB3*-GOF retinas
were dissected on ice-cold PBS and both retinas of each pup were pooled together in the same
tube. Cell lysates were prepared as described for using NP-40 lysis buffer and protein levels were
quantified using the Micro BCA™ Protein Assay Kit. Measurements of lactate were then
performed using a high sensitivity Lactate Colorimetric/Fluorometric Assay Kit as per the
manufacturer's protocol (K607-100; BioVision; CA, USA) and normalized to protein levels.

Imaging, quantification and figure preparation. Retinal cross sections were imaged using Leica
DM18 inverted fluorescent microscope and Leica Application Suite X (LASX) software for cell
counts (Leica Biosystems, Canada) or a Nikon A1 laser scanning confocal microscope at
Sunnybrook Research Institute Centre for Cytometry and Scanning Microscopy (Nikon,
Canada). OS measurements were performed by imaging three different retinal cross sections
stained with rhodopsin (n=3) of each of three different biological replicates (N=3) for each
animal group. Outer segments were then outlined using ImageJ and the total area was calculated.

Statistical analysis. Statistical analysis was performed on at least three different animals/explants
(N; biological replicates). Cell counts were performed by counting cells in three different cross
sections (n; technical replicates). For comparisons between two groups, Unpaired two-tailed
Student's t-test was used (GraphPad Prism, USA). For comparisons involving more than two
groups, one-way ANOVA with post-hoc Tukey multiple comparisons of means was used
(GraphPad Prism, USA). Results were plotted on graphs with standard error of the mean (SEM)
error bars (GraphPad Prism, USA). A p-value less than 0.05 was considered statistically
significant.

750 ACKNOWLEDGEMENTS AND FUNDING SOURCES

We would like to thank Alexander Aulehla for providing the *cytoPFKFB3* transgenic mice. We
thank Olivier Pourquié for providing reagents, Robert Cantrup in the Schuurmans' lab and Petia
Stefanova in the SRI Histology Facility for help with sectioning and immunostaining, and Cathy
Ioria in RS lab for help with the Seahorse assay. This work was supported by the Canadian
Institutes of Health Research (CIHR) PJT 180243 to CS, RS, YT and IK, and PJT – 400973 to
IA and CS. JH was supported by a Canada Graduate Scholarship – Doctoral (CGS-D)/CIHR
award, Vision Science Research Program Scholarship, Ontario Graduate Scholarship and R.O.
Torrance Bursary. CS holds the Dixon Family Chair in Ophthalmology Research at the
Sunnybrook Research Institute.

761 FIGURE LEGENDS

762 Figure 1. Glycolysis expression during development and accelerated development in *Pten-*
763 cKO retinas.

(**A**) UMAP plot of scRNA-seq data collected from wild-type retinas between E11 and P14 (Clark
et al., 2019). Stages of data collection are color-coded in the first panel, and cell type annotation
is color coded in the second panel. Pre-neurogenic (N)-RPC, early RPC and late RPC clusters are
labeled.

(**B**) Feature plots showing the transcript distribution of *Cdk1*, a marker of proliferating RPCs,
and glycolytic genes, including *Pgk1*, *Eno1*, *Hk1*, *Pfkl*, *Slc16a3*, *Aldoa,* and *Ldhb*, showing
enriched *Pgk1, Eno1* and *Hk1* expression in earlier-staged RPCs. Pre-neurogenic (N)-RPC, early
RPC and late RPC clusters are labeled.
772
(**C**) Schematic illustration of the bell curve-like distribution of rod photoreceptor differentiation
and glycolytic activity, which peak at the same period during development.

(**D**) E18.5 retinal cross sections immunostained with PAX6, PTEN, and VSX2.

(**E**) Schematic of the strategy used to generate *Pten*-cKO animals.

(**F**) Immunostaining of P0 Pax6-Cre-GFP and *Pten*-cKO retinas, showing GFP expression in
RPCs throughout the retina, with higher levels in the periphery in the ciliary marginal zone
(CMZ).

(G) Retinal cross sections of wild-type and *Pten*-cKO animals at P14 injected with BrdU at P4,
showing immunostaining with PTEN (green) and BrdU (red) in wild-type and *Pten*-cKO retinas.

(H) Quantification of the number of BrdU cells in the gcl, inl and onl. Plots show means ± SEM.
N=3 biological replicates/genotype, all with 3 technical replicates. P-value calculated with
unpaired t-test. onl, outer nuclear layer; inl, inner nuclear layer; gcl, ganglion cell layer.

(I) Graph showing differentiation pattern during retinal development in *Pten* cKO and wild-type
animals.

onbl, outer neuroblast layer; inl, inner nuclear layer; gcl, ganglion cell layer; le, lens; cmz, ciliary
marginal zone. Scale bar 50μM in C, 400μM in E and 100μM in F.

Figure 1– Figure supplement 1. Expression of *Pten* and mature photoreceptor markers
during murine retinal development.

UMAP plot of scRNA-seq data collected from wild-type retinas between E11 and P14 (Clark et
al., 2019). Transcript distribution of *Pten*, and mature photoreceptor markers (*Prph2, Impg2,*
Pde6g, Gm11744, Gnat2) at different stages of retinal development.

Figure 2. Glycolytic gene expression and activity are elevated in P0 *Pten*-cKO retinas.

(A) Heat map of bulk RNAseq data comparing gene expression in P0 *Pten*-cKO (N=5) and wild-
type (N=4) retinas.

(B) Volcano plot of DEGs with Log2FC=2, showing both down-regulated (to the left) and up-
regulated (to the right) genes. Venn diagram shows 667 up-regulated genes and 408 down-
regulated genes in P0 *Pten*-cKO retinas.

(C) KEGG pathway enrichment related to DEGs, showing an enrichment of up-regulated
glycolytic pathway genes in P0 *Pten*-cKO retinas (arrow).

(D) Schematic of glycolysis pathway, showing the intracellular enzymes involved in
metabolizing glucose into lactate. Also shown is the Slc16a3 symporter, which extrudes lactate
and H^+ to increase intracellular pHi.

(E) Normalized RPKM (reads per kilobase million) values for glycolytic gene expression in P0
wild-type and *Pten*-cKO retinas. Plots show means ± SEM. N=4 biological replicates for wild-
type and N=5 for *Pten*-cKO retinas. P-values calculated with Wald test, with a Benjamini-
Hickberg correction for multiple comparisons.

(F) Normalized glycolytic gene expression from qPCR of P0 *Pten*-cKO (N=3) and wild-type
control (N=3) retinas. Plots show means ± SEM. N=3 biological replicates/genotype, all with 3
technical replicates. P-values calculated with unpaired t-test.

(G) Seahorse assay on P0 wild-type and *Pten*-cKO RPCs cultured in vitro. Points of treatment
with oligomycin (O), FCCP (F), and Rotenone/Antimycin A (R/A) are indicated. Left plot shows
elevated extracellular acidification rate (ECAR) in *Pten*-cKO RPCs, while plot to the right shows
no significant effect on oxygen consumption rate (OCR). Plots show means ± SEM. N=3
biological replicates for *Pten*-cKO and N=8 biological replicates for wild-type, all with 3
technical replicates. P-values calculated with unpaired t-test (GraphPad Prism, USA).

(**H**) Lactate assay on P0 wild-type and *Pten*-cKO retinas. Plots show means ± SEM. N=3
biological replicates/genotype, all with 3 technical replicates. P-value calculated with unpaired t-
test.

Figure 2– Data supplement 1. RNA-seq analysis of P0 *Pten*-cKO and wild-type retinas.

Figure 3. Glycolytic inhibition reduces proliferation and photoreceptor differentiation in
P0 retinal explants.

(**A**) Schematic of retinal explant experiments, showing treatment with pharmacological inhibitors
(2DG or GPI), and the labeling of proliferating RPCs (30 min BrdU) or birthdating of newborn
retinal cells (24 hr BrdU).

(**B**) Schematic of glucose uptake replaced by 2DG, which leads to the accumulation of 2-DG-6P
that cannot be further metabolized by the glycolytic pathway.

(**C**) P0 retinal explants treated with 5mM or 10mM 2DG for 1 day in vitro (DIV), showing BrdU
immunolabeling and the number of BrdU$^+$ cells after a 30 min labeling with BrdU.

(**D**) P0 retinal explants treated with 5mM or 10 mM 2DG for 1 day in vitro (DIV), showing
BrdU immunolabeling and the number of BrdU$^+$ cells after a 24-hr labeling with BrdU, including
co-labeling with Ki67 to calculate the p-fraction (%BrdU$^+$Ki67$^+$cells/total Ki67$^+$ cells).

(**E-G**) P0 retinal explants treated with 5 mM or 10 mM 2DG for 1 day in vitro (DIV) and
immunostained for Vsx2 (E), CC3 (F) or CRX (G).

(**H**) P0 retinal explants treated with glycogen phosphorylase inhibitor (GPI) at 12.5 μM and 25
μM for 24 hr and immunostained for BrdU after a 30 min incubation at the end of the treatment
period.

Plots in C-H show means ± SEM. N=3 biological replicates/treatment, all with 3 technical
replicates. P-values calculated with one-way ANOVA with Tukey post hoc test. Scale bars= 25
μM in C, E and G, and 50 μM in D, F and H.

Figure 4. Promotion of glycolytic flux with a cyto*PFKB3*-GOF mouse model accelerates
photoreceptor differentiation and outer segment maturation.

(**A**) Schematic showing function of PFKB3 as an activator of PFK1 through the conversion of
fructose-6-phosphate to fructose-2,6-bisphosphate.

(**B**) Schematic showing generation of an RPC-specific cyto*PFKB3*-GOF mouse model.

(**C**) Lactate assay performed on P0 wild-type and cyto*PFKB3*-GOF retinas.

(**D,E**) Birthdating experiments performed by injecting BrdU into pregnant females at E12.5 and
harvesting retinas at P7. BrdU immunostaining of P7 wild-type and cyto*PFKB3*-GOF retinas (D)
and quantification of the %BrdU$^+$ cells in each of the nuclear layers (E).

(**F**) Rhodopsin immunostaining of P7 wild-type and cyto*PFKB3*-GOF retinas. An expansion of
outer segment (OS) area is indicated by the arrow and quantified in the graph.

(G) Bulk RNAseq mining of photoreceptor outer segment genes de-regulated in P0 *Pten*-cKO
retinas.

(H) Schematic of mode of action of 2DG.

(**I**) Rhodopsin immunostaining of P7 wild-type and *Pten*-cKO retinas, either without treatment or
following the administration of 2DG between P0-P7. The expanded OS area in *Pten*-cKO retinas
is indicated with an arrow. Quantifications of photoreceptor OS areas are shown in the graph.

Plots show means ± SEM. N=3 biological replicates/treatment group except C, with
cytoPFKFB3-GOF (N=3) and wild-type (N=2), all with 3 technical replicates. P-values
calculated with t-tests in C and F, and one-way ANOVA with Tukey post hoc test in E and G.
Scale bars 100 μM in E and 50 μM in F and G. gcl, ganglion cell layer; inl, inner nuclear layer;
onl, outer nuclear layer; os, outer segments.

Figure 5. Reducing intracellular pH (pHi) inhibits RPC proliferation and differentiation.
(A) Schematic showing function of Slc16a1/3 symporters in extruding lactate and H^+ out of the
cell to increase pHi during elevated glycolysis. Also depicted is the impact of acidic pH and
oligomerizing PKM to prevent its activity.

(B) Schematic of retinal explant experiments, showing treatment with a
pharmacological inhibitor (CNCn) of Slc16a symporters or growth in different pH media, and
the labeling of proliferating RPCs (30 min BrdU) or birthdating of newborn retinal cells (24 hr
BrdU).

(C) P0 retinal explants treated with 5mM CNCn for 1 day in vitro (DIV) followed by a 30 min
BrdU pulse, showing immunolabeling and the quantification of $BrdU^+$ RPCs.

(D) P0 retinal explants incubated in media buffered to pH6.5, pH7.4 or pH8.0 for 1 day in vitro
(DIV), showing BrdU immunolabeling and the number of $BrdU^+$ cells after a 30 min labeling
with BrdU.

(E) P0 retinal explants incubated in media buffered to pH6.5, pH7.4 or pH8.0 for 1 DIV,
showing BrdU immunolabeling and the number of $BrdU^+$ cells after a 24-hr labeling with BrdU,
including co-labeling with Ki67 to calculate the p-fraction ($\%BrdU^+Ki67^+$cells/total $Ki67^+$ cells).

(F-H) P0 retinal explants incubated in media buffered to pH6.5, pH7.4 or pH8.0 for 1 DIV and
immunostained for Vsx2 (E), CC3 (F) or CRX(G).

(I) P3 retinal explant electroporated with pHluorin-tdTomato, imaged after 2DIV to show
electroporated cells ($tdTomato^+$) have varying levels of 488nm emission from pHLuorin (green).

Plots show means ± SEM. N=3 biological replicates/treatment group, all with 3 technical
replicates. P-values calculated with t-tests in C, and one-way ANOVA with Tukey post hoc test
in D,E,F-H. Scale bars= 25 μM in C, D, F and H, and 50 μM in E, G and I.

Figure 6. Wnt signalling is a downstream mediator of Pten and glycolysis.

(A) Schematic illustration of canonical Wnt signaling pathway.

(B) UMAP plot of scRNA-seq data collected from wild-type retinas between E11 and P14 (Clark
et al., 2019). Transcript distribution of *Wnt7b*, *Lef1* and *Dkk1* Wnt genes.

(C) Normalized RPKM (reads per kilobase million) values for Wnt pathway-associated genes in P0 wild-type (N=4) and *Pten*-cKO (N=5) retinas.

(D) Western blot of β-catenin expression, normalized to β-actin levels, in P0 retinal explants treated with 5mM and 10mM 2DG or in P0 retinal explants cultured in media buffered to pH8.0, pH7.4 or pH6.5 **(E)**, all for 24 hrs.

Plots show means ± SEM. N=3 biological replicates/treatment group, all with 3 technical replicates. P-values calculated with t-tests in C, and one-way ANOVA with Tukey post hoc test in D,E.

Figure 6 – Figure supplement 1. Upregulation of Wnt-associated genes in *Pten* cKO retinas. PANTHER (protein analysis through evolutionary relationships) classification analysis of DEGs of P0 bulk RNAseq showing upregulation of Wnt signaling and glycolysis (arrows).

Figure 7. Wnt signaling modulate retinal proliferation and differentiation.

(A-C) P0 retinal explants treated with 5μM or 10μM FH535 to block Wnt signaling for 1 day in vitro (DIV), followed by immunostaining for BrdU after a 30 min pulse (A), CRX (B) or CC3 (C).

(D) Immunostaining P14 wild-type and *Ctnnb1*-cKO retinas with rhodopsin. Asterisk points to ONL rosette in *Ctnnb1*-cKO retina. Graph showing quantification of OS area.

(**E**) Retinal cross sections of P0 wild-type explants treated with 5mM, 10mM and 20mM sodium acetate for 1 day in vitro, along with vehicle controls, and pulsed with BrdU 30 minutes before harvesting. The number of BrdU$^+$ RPCs increased in sodium acetate treated explants.

(F) Summary of the main conclusions of the study, showing that elevated glycolytic flux increases pHi and Wnt signaling.

All experiments included three biological replicates for each group. Statistical analysis was done using one-way ANOVA with Tukey post hoc test used in A-C and unpaired *t*-test in D. Scale bars= 50 μM in A-D. gcl, ganglion cell layer; inl, inner nuclear layer; onl, outer nuclear layer; os, outer segments.

REFERENCES

Agathocleous, M., Love, N. K., Randlett, O., Harris, J. J., Liu, J., Murray, A. J., & Harris, W. A. (2012, Aug). Metabolic differentiation in the embryonic retina. *Nat Cell Biol, 14*(8), 859-864. https://doi.org/10.1038/ncb2531

Alexiades, M. R., & Cepko, C. L. (1997, Mar). Subsets of retinal progenitors display temporally regulated and distinct biases in the fates of their progeny. *Development, 124*(6), 1119-1131. https://doi.org/10.1242/dev.124.6.1119

939 Backman, S. A., Stambolic, V., Suzuki, A., Haight, J., Elia, A., Pretorius, J., Tsao, M. S., Shannon, P.,
940   Bolon, B., Ivy, G. O., & Mak, T. W. (2001, Dec). Deletion of Pten in mouse brain causes
941   seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. *Nat Genet, 29*(4),
942   396-403. https://doi.org/10.1038/ng782
943

944 Baye, L. M., & Link, B. A. (2007, Sep 19). Interkinetic nuclear migration and the selection of neurogenic
945   cell divisions during vertebrate retinogenesis. *J Neurosci, 27*(38), 10143-10152.
946   https://doi.org/10.1523/JNEUROSCI.2754-07.2007
947

948 Borges, G. A., Webber, L. P., AE, M. M., Guerra, E. N., Castilho, R. M., & Squarize, C. H. (2020, Feb).
949   Pharmacological PTEN inhibition: potential clinical applications and effects in tissue
950   regeneration. *Regen Med, 15*(2), 1329-1344. https://doi.org/10.2217/rme-2019-0065
951

952 Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018, Jun). Integrating single-cell
953   transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol, 36*(5),
954   411-420. https://doi.org/10.1038/nbt.4096
955

956 Cantrup, R., Dixit, R., Palmesino, E., Bonfield, S., Shaker, T., Tachibana, N., Zinyk, D., Dalesman, S.,
957   Yamakawa, K., Stell, W. K., Wong, R. O., Reese, B. E., Kania, A., Sauve, Y., & Schuurmans, C.
958   (2012). Cell-type specific roles for PTEN in establishing a functional retinal architecture. *PLoS
959   One, 7*(3), e32795. https://doi.org/10.1371/journal.pone.0032795
960

961 Carthew, R. W. (2021, Apr). Gene Regulation and Cellular Metabolism: An Essential Partnership. *Trends
962   Genet, 37*(4), 389-400. https://doi.org/10.1016/j.tig.2020.09.018
963

964 Cepko, C. (2014, 2014/09/01). Intrinsically different retinal progenitor cells produce specific types of
965   progeny. *Nature Reviews Neuroscience, 15*(9), 615-627. https://doi.org/10.1038/nrn3767
966

Cereghetti, G., Kissling, V. M., Koch, L. M., Arm, A., Schmidt, C. C., Thüringer, Y., Zamboni, N.,
Afanasyev, P., Linsenmeier, M., Eichmann, C., Kroschwald, S., Zhou, J., Cao, Y., Pfizenmaier,
D. M., Wiegand, T., Cadalbert, R., Gupta, G., Boehringer, D., Knowles, T. P. J., Mezzenga, R.,
Arosio, P., Riek, R., & Peter, M. (2024, May 21). An evolutionarily conserved mechanism
controls reversible amyloids of pyruvate kinase via pH-sensing regions. *Dev Cell*.
https://doi.org/10.1016/j.devcel.2024.04.018
973

974 Chinchore, Y., Begaj, T., Wu, D., Drokhlyansky, E., & Cepko, C. L. (2017, Jun 9). Glycolytic reliance
975   promotes anabolism in photoreceptors. *Elife, 6*. https://doi.org/10.7554/eLife.25946
976

977 Clark, B. S., Stein-O'Brien, G. L., Shiau, F., Cannon, G. H., Davis-Marcisak, E., Sherman, T., Santiago,
978   C. P., Hoang, T. V., Rajaii, F., James-Esposito, R. E., Gronostajski, R. M., Fertig, E. J., Goff, L.
979   A., & Blackshaw, S. (2019, Jun 19). Single-Cell RNA-Seq Analysis of Retinal Development
980   Identifies NFI Factors as Regulating Mitotic Exit and Late-Born Cell Specification. *Neuron,
981   102*(6), 1111-1126 e1115. https://doi.org/10.1016/j.neuron.2019.04.010
982

983 Czowski, B. J., & White, K. A. (2024, Mar 27). Intracellular pH regulates β-catenin with low pHi
984   increasing adhesion and signaling functions. *bioRxiv*. https://doi.org/10.1101/2024.03.22.586349
985

986 Datta, P., Allamargot, C., Hudson, J. S., Andersen, E. K., Bhattarai, S., Drack, A. V., Sheffield, V. C., &
987   Seo, S. (2015, Aug 11). Accumulation of non-outer segment proteins in the outer segment
988   underlies photoreceptor degeneration in Bardet-Biedl syndrome. *Proc Natl Acad Sci U S A,
989   112*(32), E4400-4409. https://doi.org/10.1073/pnas.1510111112

990
991 Esteban-Martinez, L., Sierra-Filardi, E., McGreal, R. S., Salazar-Roa, M., Marino, G., Seco, E., Durand,
992   S., Enot, D., Grana, O., Malumbres, M., Cvekl, A., Cuervo, A. M., Kroemer, G., & Boya, P.
993   (2017, Jun 14). Programmed mitophagy is essential for the glycolytic switch during cell
994   differentiation. *EMBO J, 36*(12), 1688-1706. https://doi.org/10.15252/embj.201695916
995
996 Fekete, D. M., Perez-Miguelsanz, J., Ryder, E. F., & Cepko, C. L. (1994, Dec). Clonal analysis in the
997   chicken retina reveals tangential dispersion of clonally related cells. *Dev Biol, 166*(2), 666-682.
998   https://doi.org/10.1006/dbio.1994.1346
999
1000 Gomes, F. L., Zhang, G., Carbonell, F., Correa, J. A., Harris, W. A., Simons, B. D., & Cayouette, M.
1001   (2011, Jan). Reconstruction of rat retinal progenitor cell lineages in vitro reveals a surprising
1002   degree of stochasticity in cell fate decisions. *Development, 138*(2), 227-235.
1003   https://doi.org/10.1242/dev.059683
1004
1005 Hafler, B. P., Surzenko, N., Beier, K. T., Punzo, C., Trimarchi, J. M., Kong, J. H., & Cepko, C. L. (2012,
1006   May 15). Transcription factor Olig2 defines subpopulations of retinal progenitor cells biased
1007   toward specific cell fates. *Proc Natl Acad Sci U S A, 109*(20), 7882-7887.
1008   https://doi.org/10.1073/pnas.1203138109
1009
1010 Handeli, S., & Simon, J. A. (2008, Mar). A small-molecule inhibitor of Tcf/beta-catenin signaling down-
1011   regulates PPARgamma and PPARdelta activities. *Mol Cancer Ther, 7*(3), 521-529.
1012   https://doi.org/10.1158/1535-7163.Mct-07-2063
1013
1014 Hanna, J., David, L. A., Touahri, Y., Fleming, T., Screaton, R. A., & Schuurmans, C. (2022). Beyond
1015   Genetics: The Role of Metabolism in Photoreceptor Survival, Development and Repair. *Front
1016   Cell Dev Biol, 10*, 887764. https://doi.org/10.3389/fcell.2022.887764
1017
1018 Harrison-Uy, S. J., & Pleasure, S. J. (2012, Jul 1). Wnt signaling and forebrain development. *Cold Spring
1019   Harb Perspect Biol, 4*(7), a008094. https://doi.org/10.1101/cshperspect.a008094
1020
1021 Hauck, L., Dadson, K., Chauhan, S., Grothe, D., & Billia, F. (2021, Apr). Inhibiting the Pkm2/b-catenin
1022   axis drives in vivo replication of adult cardiomyocytes following experimental MI. *Cell Death
1023   Differ, 28*(4), 1398-1417. https://doi.org/10.1038/s41418-020-00669-9
1024
1025 He, J., Zhang, G., Almeida, Alexandra D., Cayouette, M., Simons, Benjamin D., & Harris, William A.
1026   (2012, 2012/09/06/). How Variable Clones Build an Invariant Retina. *Neuron, 75*(5), 786-798.
1027   https://doi.org/https://doi.org/10.1016/j.neuron.2012.06.033
1028
1029 Holt, C. E., Bertsch, T. W., Ellis, H. M., & Harris, W. A. (1988, Mar). Cellular determination in the
1030   Xenopus retina is independent of lineage and birth date. *Neuron, 1*(1), 15-26.
1031   https://doi.org/10.1016/0896-6273(88)90205-x
1032
1033 Hurley, J. B., Lindsay, K. J., & Du, J. (2015, Jul). Glucose, lactate, and shuttling of metabolites in
1034   vertebrate retinas. *J Neurosci Res, 93*(7), 1079-1092. https://doi.org/10.1002/jnr.23583
1035
1036 Javed, A., & Cayouette, M. (2017). Temporal Progression of Retinal Progenitor Cell Identity:
1037   Implications in Cell Replacement Therapies. *Front Neural Circuits, 11*, 105.
1038   https://doi.org/10.3389/fncir.2017.00105
1039

1040   Jensen, A. M., & Raff, M. C. (1997, Aug 15). Continuous observation of multipotential retinal progenitor
1041   cells in clonal density culture. *Dev Biol, 188*(2), 267-279. https://doi.org/10.1006/dbio.1997.8645
1042
1043   Jo, H. S., Kang, K. H., Joe, C. O., & Kim, J. W. (2012, Feb 15). Pten coordinates retinal neurogenesis by
1044   regulating Notch signalling. *EMBO J, 31*(4), 817-828. https://doi.org/10.1038/emboj.2011.443
1045
1046   Khacho, M., & Slack, R. S. (2018, Jan). Mitochondrial dynamics in the regulation of neurogenesis: From
1047   development to the adult brain. *Dev Dyn, 247*(1), 47-53. https://doi.org/10.1002/dvdy.24538
1048
1049   Kim, J. W., Yang, H. J., Brooks, M. J., Zelinger, L., Karakülah, G., Gotoh, N., Boleda, A., Gieser, L.,
1050   Giuste, F., Whitaker, D. T., Walton, A., Villasmil, R., Barb, J. J., Munson, P. J., Kaya, K. D.,
1051   Chaitankar, V., Cogliati, T., & Swaroop, A. (2016, Nov 22). NRL-Regulated Transcriptome
1052   Dynamics of Developing Rod Photoreceptors. *Cell Rep, 17*(9), 2460-2473.
1053   https://doi.org/10.1016/j.celrep.2016.10.074
1054
1055   Knafo, S., & Esteban, J. A. (2017, Feb). PTEN: Local and Global Modulation of Neuronal Function in
1056   Health and Disease. *Trends Neurosci, 40*(2), 83-91. https://doi.org/10.1016/j.tins.2016.11.008
1057
1058   Koch, L. M., Birkeland, E. S., Battaglioni, S., Helle, X., Meerang, M., Hiltbrunner, S., Ibáñez, A. J.,
1059   Peter, M., Curioni-Fontecedro, A., Opitz, I., & Dechant, R. (2020, Nov). Cytosolic pH regulates
1060   proliferation and tumour growth by promoting expression of cyclin D1. *Nat Metab, 2*(11), 1212-
1061   1222. https://doi.org/10.1038/s42255-020-00297-0
1062
1063   Kochanowski, K., Volkmer, B., Gerosa, L., Haverkorn van Rijsewijk, B. R., Schmidt, A., & Heinemann,
1064   M. (2013, Jan 15). Functioning of a metabolic flux sensor in Escherichia coli. *Proc Natl Acad Sci
1065   U S A, 110*(3), 1130-1135. https://doi.org/10.1073/pnas.1202582110
1066
1067   Kubo, F., Takeichi, M., & Nakagawa, S. (2005, Jun). Wnt2b inhibits differentiation of retinal progenitor
1068   cells in the absence of Notch activity by downregulating the expression of proneural genes.
1069   *Development, 132*(12), 2759-2770. https://doi.org/10.1242/dev.01856
1070
1071   Laroche, S., Stil, A., Germain, P., Cherif, H., Chemtob, S., & Bouchard, J. F. (2021, Jun 30). Participation
1072   of L-Lactate and Its Receptor HCAR1/GPR81 in Neurovisual Development. *Cells, 10*(7).
1073   https://doi.org/10.3390/cells10071640
1074
1075   Marquardt, T., Ashery-Padan, R., Andrejewski, N., Scardigli, R., Guillemot, F., & Gruss, P. (2001, Apr
1076   6). Pax6 is required for the multipotent state of retinal progenitor cells. *Cell, 105*(1), 43-55.
1077   https://doi.org/10.1016/s0092-8674(01)00295-1
1078
1079   Melnik, S., Dvornikov, D., Müller-Decker, K., Depner, S., Stannek, P., Meister, M., Warth, A., Thomas,
1080   M., Muley, T., Risch, A., Plass, C., Klingmüller, U., Niehrs, C., & Glinka, A. (2018). Cancer cell
1081   specific inhibition of Wnt/β-catenin signaling by forced intracellular acidification. *Cell Discov, 4*,
1082   37. https://doi.org/10.1038/s41421-018-0033-2
1083
1084   Miyazawa, H., Snaebjornsson, M. T., Prior, N., Kafkia, E., Hammaren, H. M., Tsuchida-Straeten, N.,
1085   Patil, K. R., Beck, M., & Aulehla, A. (2022, Dec 5). Glycolytic flux-signaling controls mouse
1086   embryo mesoderm development. *Elife, 11*. https://doi.org/10.7554/eLife.83299
1087
1088   Nerli, E., Rocha-Martins, M., & Norden, C. (2020, Nov 3). Asymmetric neurogenic commitment of
1089   retinal progenitors involves Notch through the endocytic pathway. *Elife, 9*.
1090   https://doi.org/10.7554/eLife.60462

1091
1092 Oginuma, M., Harima, Y., Tarazona, O. A., Diaz-Cuadros, M., Michaut, A., Ishitani, T., Xiong, F., &
1093   Pourquie, O. (2020, Aug). Intracellular pH controls WNT downstream of glycolysis in amniote
1094   embryos. *Nature, 584*(7819), 98-101. https://doi.org/10.1038/s41586-020-2428-0
1095
1096 Ouchi, Y., Baba, Y., Koso, H., Taketo, M. M., Iwamoto, T., Aburatani, H., & Watanabe, S. (2011,
1097   2011/04/01). β-Catenin signaling regulates the timing of cell differentiation in mouse retinal
1098   progenitor cells. *Molecular and Cellular Neuroscience, 46*(4), 770-780.
1099   https://doi.org/https://doi.org/10.1016/j.mcn.2011.02.010
1100
1101 Paolini, A., Duchemin, A. L., Albadri, S., Patzel, E., Bornhorst, D., Gonzalez Avalos, P., Lemke, S.,
1102   Machate, A., Brand, M., Sel, S., Di Donato, V., Del Bene, F., Zolessi, F. R., Ramialison, M., &
1103   Poggi, L. (2015, Mar 1). Asymmetric inheritance of the apical domain and self-renewal of retinal
1104   ganglion cell progenitors depend on Anillin function. *Development, 142*(5), 832-839.
1105   https://doi.org/10.1242/dev.118612
1106
1107 Park, K. K., Liu, K., Hu, Y., Smith, P. D., Wang, C., Cai, B., Xu, B., Connolly, L., Kramvis, I., Sahin, M.,
1108   & He, Z. (2008, Nov 7). Promoting axon regeneration in the adult CNS by modulation of the
1109   PTEN/mTOR pathway. *Science, 322*(5903), 963-966. https://doi.org/10.1126/science.1161566
1110
1111 Peeters, K., Van Leemputte, F., Fischer, B., Bonini, B. M., Quezada, H., Tsytlonok, M., Haesen, D.,
1112   Vanthienen, W., Bernardes, N., Gonzalez-Blas, C. B., Janssens, V., Tompa, P., Versees, W., &
1113   Thevelein, J. M. (2017, Oct 13). Fructose-1,6-bisphosphate couples glycolytic flux to activation
1114   of Ras. *Nat Commun, 8*(1), 922. https://doi.org/10.1038/s41467-017-01019-z
1115
1116 Peng, M., Yin, N., Chhangawala, S., Xu, K., Leslie, C. S., & Li, M. O. (2016). Aerobic glycolysis
1117   promotes T helper 1 cell differentiation through an epigenetic mechanism. *Science, 354*(6311),
1118   481-484. https://doi.org/doi:10.1126/science.aaf6284
1119
1120 Qian, X., Li, X., Shi, Z., Xia, Y., Cai, Q., Xu, D., Tan, L., Du, L., Zheng, Y., Zhao, D., Zhang, C.,
1121   Lorenzi, P. L., You, Y., Jiang, B. H., Jiang, T., Li, H., & Lu, Z. (2019, Nov 7). PTEN Suppresses
1122   Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1. *Mol Cell, 76*(3),
1123   516-527.e517. https://doi.org/10.1016/j.molcel.2019.08.006
1124
1125 Rapaport, D. H., Wong, L. L., Wood, E. D., Yasumura, D., & LaVail, M. M. (2004, Jun 21). Timing and
1126   topography of cell genesis in the rat retina. *J Comp Neurol, 474*(2), 304-324.
1127   https://doi.org/10.1002/cne.20134
1128
1129 Ryall, J. G., Dell'Orso, S., Derfoul, A., Juan, A., Zare, H., Feng, X., Clermont, D., Koulnis, M., Gutierrez-
1130   Cruz, G., Fulco, M., & Sartorelli, V. (2015, Feb 5). The NAD(+)-dependent SIRT1 deacetylase
1131   translates a metabolic switch into regulatory epigenetics in skeletal muscle stem cells. *Cell Stem
1132   Cell, 16*(2), 171-183. https://doi.org/10.1016/j.stem.2014.12.004
1133
1134 Sakagami, K., Chen, B., Nusinowitz, S., Wu, H., & Yang, X. J. (2012, Feb). PTEN regulates retinal
1135   interneuron morphogenesis and synaptic layer formation. *Mol Cell Neurosci, 49*(2), 171-183.
1136   https://doi.org/10.1016/j.mcn.2011.11.007
1137
1138 Schmidt, M., Tanaka, M., & Münsterberg, A. (2000, Oct). Expression of (beta)-catenin in the developing
1139   chick myotome is regulated by myogenic signals. *Development, 127*(19), 4105-4113.
1140   https://doi.org/10.1242/dev.127.19.4105
1141

Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012, Jul). NIH Image to ImageJ: 25 years of image analysis. *Nat Methods, 9*(7), 671-675. https://doi.org/10.1038/nmeth.2089

Shi, L., Pan, H., Liu, Z., Xie, J., & Han, W. (2017, 2017/11/24). Roles of PFKFB3 in cancer. *Signal Transduction and Targeted Therapy, 2*(1), 17044. https://doi.org/10.1038/sigtrans.2017.44

Tachibana, N., Cantrup, R., Dixit, R., Touahri, Y., Kaushik, G., Zinyk, D., Daftarian, N., Biernaskie, J., McFarlane, S., & Schuurmans, C. (2016, Sep 7). Pten Regulates Retinal Amacrine Cell Number by Modulating Akt, Tgfbeta, and Erk Signaling. *J Neurosci, 36*(36), 9454-9471. https://doi.org/10.1523/JNEUROSCI.0936-16.2016

Tachibana, N., Touahri, Y., Dixit, R., David, L. A., Adnani, L., Cantrup, R., Aavani, T., Wong, R. O., Logan, C., Kurek, K. C., & Schuurmans, C. (2018, May 21). Hamartoma-like lesions in the mouse retina: an animal model of Pten hamartoma tumour syndrome. *Dis Model Mech, 11*(5). https://doi.org/10.1242/dmm.031005

Takata, N., Miska, J. M., Morgan, M. A., Patel, P., Billingham, L. K., Joshi, N., Schipma, M. J., Dumar, Z. J., Joshi, N. R., Misharin, A. V., Embry, R. B., Fiore, L., Gao, P., Diebold, L. P., McElroy, G. S., Shilatifard, A., Chandel, N. S., & Oliver, G. (2023, Jul 14). Lactate-dependent transcriptional regulation controls mammalian eye morphogenesis. *Nat Commun, 14*(1), 4129. https://doi.org/10.1038/s41467-023-39672-2

Tatapudy, S., Aloisio, F., Barber, D., & Nystul, T. (2017, Dec). Cell fate decisions: emerging roles for metabolic signals and cell morphology. *EMBO Rep, 18*(12), 2105-2118. https://doi.org/10.15252/embr.201744816

Touahri, Y., Hanna, J., Tachibana, N., Okawa, S., Liu, H., David, L. A., Olender, T., Vasan, L., Pak, A., Mehta, D. N., Chinchalongporn, V., Balakrishnan, A., Cantrup, R., Dixit, R., Mattar, P., Saleh, F., Ilnytskyy, Y., Murshed, M., Mains, P. E., Kovalchuk, I., Lefebvre, J. L., Leong, H. S., Cayouette, M., Wang, C., Sol, A. D., Brand, M., Reese, B. E., & Schuurmans, C. (2024, Mar 27). Pten regulates endocytic trafficking of cell adhesion and Wnt signaling molecules to pattern the retina. *Cell Rep, 43*(4), 114005. https://doi.org/10.1016/j.celrep.2024.114005

Turner, D. L., & Cepko, C. L. (1987, Jul 9-15). A common progenitor for neurons and glia persists in rat retina late in development. *Nature, 328*(6126), 131-136. https://doi.org/10.1038/328131a0

Turner, D. L., Snyder, E. Y., & Cepko, C. L. (1990, Jun). Lineage-independent determination of cell type in the embryonic mouse retina. *Neuron, 4*(6), 833-845. https://doi.org/10.1016/0896-6273(90)90136-4

Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009, May 22). Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science, 324*(5930), 1029-1033. https://doi.org/10.1126/science.1160809

Warburg, O. (1956a, Aug 10). On respiratory impairment in cancer cells. *Science, 124*(3215), 269-270. https://www.ncbi.nlm.nih.gov/pubmed/13351639

Warburg, O. (1956b, Feb 24). On the origin of cancer cells. *Science, 123*(3191), 309-314. https://doi.org/10.1126/science.123.3191.309

1192   Wetts, R., & Fraser, S. E. (1988, Mar 4). Multipotent precursors can give rise to all major cell types of the
1193   frog retina. *Science, 239*(4844), 1142-1145. https://doi.org/10.1126/science.2449732
1194
1195   Young, R. W. (1985, Jun). Cell differentiation in the retina of the mouse. *Anat Rec, 212*(2), 199-205.
1196   https://doi.org/10.1002/ar.1092120215
1197
1198   Zhang, C. S., Hawley, S. A., Zong, Y., Li, M., Wang, Z., Gray, A., Ma, T., Cui, J., Feng, J. W., Zhu, M.,
1199   Wu, Y. Q., Li, T. Y., Ye, Z., Lin, S. Y., Yin, H., Piao, H. L., Hardie, D. G., & Lin, S. C. (2017,
1200   Aug 3). Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK. *Nature,*
1201   *548*(7665), 112-116. https://doi.org/10.1038/nature23275
1202
1203   Zhang, K., Sun, L., & Kang, Y. (2023, 2023/09/18). Regulation of phosphoglycerate kinase 1 and its
1204   critical role in cancer. *Cell Communication and Signaling, 21*(1), 240.
1205   https://doi.org/10.1186/s12964-023-01256-4
1206
1207   Zhang, X., Leavey, P., Appel, H., Makrides, N., & Blackshaw, S. (2023, Oct). Molecular mechanisms
1208   controlling vertebrate retinal patterning, neurogenesis, and cell fate specification. *Trends Genet,*
1209   *39*(10), 736-757. https://doi.org/10.1016/j.tig.2023.06.002
1210
1211

Hanna et al. Figure 1

Figure 1-figure supplement 1

Hanna et al. Figure 2

Hanna et al. Figure 3

A

fructose-2,6-bisphosphate

PFKB3 ↕ ⤸ PFK1

fructose-6-phosphate → fructose-1,6-bisphosphate

B

Pax6-Cre driver

Pax6-alpha-P0 promoter — cre-GFP

X

CytoPFKB3 floxed STOP allele

CAG promoter — loxP — ▮▮▮▮ — loxP — CytoPFKB3

CytoPFKB3 conditional gain-of-function allele

loxP — CytoPFKB3

C Lactate Assay

nmol/ug Protein

p=0.023

wild-type, CytoPFKB3-GOF

D Birthdating Assay

wild-type | CytoPFKB3-GOF

onl, inl, gcl

BrdU

E Birthdating Assay

ONL — % BrdU cells/ ROI — p=0.003 — wild-type, CytoPFKB3-GOF

INL — % BrdU cells/ ROI — p=0.02 — wild-type, CytoPFKB3-GOF

GCL — % BrdU cells/ ROI — ns — wild-type, CytoPFKB3-GOF

F

wild-type P7 | CytoPFKB3-GOF P7

os, onl, inl

Rho

OS area — p=0.005 — wild-type, CytoPFKB3-GOF

G *P0 Pten-cKO*

fold-change RPKM

upregulated OS genes

Ggt7, Pcdh15, Atp2b2, Fasn, Acaca, Lrp1, Rorb, Huwe1, Lpcat1

downregulated OS genes

Nap1l1, Psmb1, Chmp5, Gm4204, Opn1sw, Pdc, Gnat2

H

Glucose, 2-DG

Glut1

2-DG → (Hk) → 2-DG-6P, 2-DG-6P, 2-DG-6P

I

wild-type P7 | *Pten*-cKO P7 | 2DG *Pten*-cKO P0-P7 2DG

os, onl, inl

Rho

OS area — p=0.0001 — p=0.0003 — wild-type, *Pten*-cKO, 2DG *Pten*-cKO

Hanna et al. Figure 4

Hanna et al. Figure 5

Gene number

20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 0

PANTHER Pathways

2-arachidonoylglycerol biosynthesis (P05726)
5HT1 type receptor mediated signaling pathway (P04373)
5HT2 type receptor mediated signaling pathway (P04374)
5HT4 type receptor mediated signaling pathway (P04376)
Alpha adrenergic receptor signaling pathway (P00002)
Alzheimer disease-amyloid secretase pathway (P00003)
Alzheimer disease-presenilin pathway (P00004)
Androgen/estrogene/progesterone biosynthesis (P02727)
Angiogenesis (P00005)
Angiotensin II-stimulated signaling through G proteins and beta-arrestin (P05911)
Apoptosis signaling pathway (P00006)
Axon guidance mediated by Slit/Robo (P00008)
Axon guidance mediated by netrins (P00009)
Axon guidance mediated by semaphorins (P00007)
B cell activation (P00010)
Beta1 adrenergic receptor signaling pathway (P04377)
Beta2 adrenergic receptor signaling pathway (P04378)
Beta3 adrenergic receptor signaling pathway (P04379)
CCKR signaling map (P06959)
Cadherin signaling pathway (P00012)
Cell cycle (P00013)
Cholesterol biosynthesis (P00014)
Circadian clock system (P00015)
Cortocotropin releasing factor receptor signaling pathway (P04380)
Cytoskeleton regulation by Rho GTPase (P00016)
De novo purine biosynthesis (P02738)
Dopamine receptor mediated signaling pathway (P05912)
EGF receptor signaling pathway (P00018)
Endogenous cannabinoid signaling (P05730)
Endothelin signaling pathway (P00019)
Enkephalin release (P05913)
FAS signaling pathway (P00020)
FGF signaling pathway (P00021)
Fructose galactose metabolism (P02744)
GABA-B receptor II signaling (P05731)
Gamma-aminobutyric acid synthesis (P04384)
Glycolysis (P00024)
Gonadotropin-releasing hormone receptor pathway (P06664)
Hedgehog signaling pathway (P00025)
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway (P00026)
Heterotrimeric G-protein signaling pathway-Gq alpha and G0 alpha mediated pathway (P00027)
Heterotrimeric G-protein signaling pathway-rod outer segment phototransduction (P00028)
Histamine H1 receptor mediated signaling pathway (P04385)
Histamine H2 receptor mediated signaling pathway (P04386)
Huntington disease (P00029)
Hypoxia response via HIF activation (P00030)
Inflammation mediated by chemokine and cytokine signaling pathway (P00031)
Insulin/IGF pathway-mitogen activated protein kinase/MAP kinase cascade (P00032)
Insulin/IGF pathway-mitogen activated protein kinase B signaling cascade (P00033)
Integrin signaling pathway (P00034)
Interferon-gamma signaling pathway (P00035)
Interleukin signaling pathway (P00036)
Ionotropic glutamate receptor pathway (P00037)
Metabotropic glutamate receptor group I pathway (P00041)
Metabotropic glutamate receptor group 2 pathway (P00040)
Metabotropic glutamate receptor group 3 pathway (P00039)
Muscarinic acetylcholine receptor 1 and 3 signaling pathway (P00042)
Muscarinic acetylcholine receptor 2 and 4 signaling pathway (P00043)
Nicotine pharmacodynamics pathway (P06587)
Nicotinic acetylcholine receptor signaling pathway (P00044)
Notch signaling pathway (P00045)
Opiod prodynorphin pathway (P05916)
Opiod proenkephalin pathway (P05915)
Opiod proopiomelanocortin pathway (P05917)
Oxidative stress response (P00046)
Oxytocin receptor mediating signaling pathway (P04391)
P53 pathway feedback loops 1 (P04392)
PDGF signaling pathway (P00047)
PI3 kinase pathway (P00048)
Parkinson disease (P00049)
Pentose phosphate pathway (P02762)
Ras pathway (P04393)
Serine glycine biosynthesis (P02776)
Synaptic vesicle trafficking (P05734)
T cell activation (P00053)
TGF-beta signaling pathway (P00052)
Thyrotropin-releasing hormone receptor signaling pathway (P04394)
Toll receptor signaling pathway (P00054)
Ubiquitin proteasome pathway (P00060)
VEGF signaling pathway (P00056)
Wnt signaling pathway (P00057)
p53 pathway by glucose deprivation (P04397)
p53 pathway feedback loops 2 (P04398)
p53 pathway (P00059)

Figure 6-figure supplement 1

Hanna et al. Figure 7